Page last updated: 2024-11-05

arginine vasopressin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID644077
CHEMBL ID373742
CHEBI ID34543
SCHEMBL ID43139
SCHEMBL ID17874853
MeSH IDM0001691

Synonyms (70)

Synonym
arginine vasopressin
argipressine
gtpl2168
(2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-5-(d
vasopressin (arginine form)
pitressin
1,2-dithia-5,8,11,14,17-pentaazacycloeicosane-10-propionamide, 19-amino-13-benzyl-7-(carbamoylmethyl)-4-[2-[[1-[(carbamoylmethyl)carbamoyl]-4-guanidinobutyl]carbamoyl]-1-pyrrolidinylcarbonyl]-16-p-hyd
beta-hypophamine
8-arginine-vasopressin
vasopressin, 8-l-arginine- (7ci,8ci,9ci)
argipressin tannate [usan]
oxytocin, 3-(l-phenylalanine)-8-l-arginine-
3-(phenylalanine)-8-arginineoxytocin
rindervasopressin
arginine-8-vasopressin
8-l-arginine-vasopressin
[8-arginine]vasopressin
arginine-vasopressin
vasophysin
glycinamide, l-cysteinyl-l-tyrosyl-l-phenylalanyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-arginyl-, cyclic (1>6)-disulfide
roxybenzyl-6,9,12,15,18-pentaoxo- (6ci)
cys-tyr-phe-gln-asn-cys-pro-arg-gly-nh2[disulfide bridge: 1-6]
argipressin
NCGC00166306-01
vasopressin, 8-l-arginine-
einecs 204-035-4
argipressine [inn-french]
argipressina [dcit]
argipresina [inn-spanish]
argipressinum [inn-latin]
NCGC00166306-02
(arg8)-vasopressin
[cyclo s-s]cyfqncprg-nh2
1-{[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-l-prolyl-l-arginylglycinamide
CHEBI:34543 ,
[3h]vasopressin
chembl373742 ,
[3h]argipressin tannate
bdbm35667
(2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminom
NCGC00188439-01
y4907o6mfd ,
argipressin [inn]
argipressin [inn:ban]
argipressina
argipressinum
argipresina
unii-y4907o6mfd
dtxsid0048349 ,
dtxcid5028324
tox21_113037
cas-113-79-1
argipressin or lypressin
SCHEMBL43139
mfcd00076738
bdbm50044777
SCHEMBL17874853
AKOS030529553
Q183011
arginine vasopressin (avp)
arg8-vasopressin;avp
argipressine (inn-french)
1-(((4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl)carbonyl)-l-prolyl-l-arginylglycinamide
therapeutic adh
(cyclo s-s)cyfqncprg-nh2
arginine vasopressin, for bioassay
recombinant antidiuretic hormone
recombinant vasopressin
argipressinum (inn-latin)
argipresina (inn-spanish)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Headache, hypotension, nausea, constipation, and postural hypotension were the most common adverse events."( Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
Brooks-Asplund, E; Fan, K; Ghali, JK; Koren, MJ; Long, WA; Smith, N; Taylor, JR, 2006
)
0.33
" The most common adverse event was mild thirst."( Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.
Azuma, J; Hasunuma, T; Kim, SR; Kondo, M; Okada, T; Sato, O, 2011
)
0.37
" The safety profile of tolvaptan was considered acceptable for clinical use with minimal adverse effects."( Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
Fukunami, M; Hori, M; Izumi, T; Matsuzaki, M, 2011
)
0.37
"The objective of this study was to compare the incidence of severe adverse events of vasopressin vs hydrocortisone for endocrine support therapy in patients with septic shock."( The impact of endocrine supplementation on adverse events in septic shock.
Bissell, BD; Erdman, MJ; Ferreira, JA; Kraemer, DF; Smotherman, C, 2015
)
0.42
"In the unmatched cohort of 124 patients, vasopressin was associated with a significant decrease in the number of severe adverse events (P=."( The impact of endocrine supplementation on adverse events in septic shock.
Bissell, BD; Erdman, MJ; Ferreira, JA; Kraemer, DF; Smotherman, C, 2015
)
0.42
"Given the lower incidence of adverse events and faster time to hemodynamic stability, vasopressin appears to be the most advantageous endocrine agent for hemodynamic support in septic shock."( The impact of endocrine supplementation on adverse events in septic shock.
Bissell, BD; Erdman, MJ; Ferreira, JA; Kraemer, DF; Smotherman, C, 2015
)
0.42
" Furthermore, no adverse events were observed in either group."( Effectiveness and safety of moxibustion for vascular dementia: A systematic review and meta-analysis.
Dong, Y; Duan, M; Jiang, X; Lu, T; Shi, J; Zhang, X, 2022
)
0.72
"Moxibustion is effective and safe in the treatment of VD, but more high-quality evidence from further studies is required to support this."( Effectiveness and safety of moxibustion for vascular dementia: A systematic review and meta-analysis.
Dong, Y; Duan, M; Jiang, X; Lu, T; Shi, J; Zhang, X, 2022
)
0.72
" Hyponatremia was the most frequently reported adverse event (n = 37, 25%)."( Efficacy and Safety of Vasopressin and Terlipressin in Preterm Neonates: A Systematic Review.
Al-Saadi, A; Bui, V; Razak, A; Samiee-Zafarghandy, S; Sushko, K; van den Anker, J, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic parameters and biological duration of action of DDAVP were measured in five patients with central diabetes insipidus of differing severity."( Pharmacokinetics of 1-desamino-8-D-arginine vasopressin (DDAVP) in patients with central diabetes insipidus.
Burger, HG; Johnston, CI; Pullan, PT, 1978
)
0.26
" The early and late hemodynamic, hormonal, pharmacokinetic and clinical responses to oral MDL 17,043 were studied in 20 patients."( MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response.
Generalovich, T; Reddy, PS; Uretsky, BF; Valdes, AM; Verbalis, JG, 1985
)
0.27
"A pharmacokinetic study was carried out to assess the bioavailability of desglycinamide-[Arg8]vasopressin (DGAVP, Org 5667)."( Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects.
Hijman, R; Laczi, F; Van Ree, JM; Westenberg, HG; Wiegant, VM, 1994
)
0.29
"8 l and the biological half-life was 39."( Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers.
Broeders, A; Lundin, S; Melin, P, 1993
)
0.29
"The half-life was longer and the clearance of antocin was less than that found in a previous study when a non-specific antiserum was used."( Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers.
Broeders, A; Lundin, S; Melin, P, 1993
)
0.29
"The pharmacologic and pharmacokinetic properties were evaluated in a series of antiuterotonic oxytocin analogs, modified at positions 1, 2, 4, 8 and, in one case, position 9 of the oxytocin (OT) molecule."( Pharmacokinetic and pharmacologic properties of antiuterotonic oxytocin analogs in the rat.
Bengtsson, HI; Broeders, A; Hansson, K; Lundin, S; Melin, P; Ohlin, M; Trojnar, J, 1993
)
0.29
" The aim of this study was to assess its tolerability and to determine both its pharmacokinetic and pharmacodynamic profiles."( Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
Brouard, R; Donat, F; Dreux, F; Fournie, D; Jang, H; Laporte, V; Lockwood, G; Pignol, R; Serradeil Le Gal, C, 1998
)
0.3
"The pharmacokinetic and pharmacodynamic interactions between tolvaptan and furosemide or hydrochlorothiazide (HCTZ) were determined in a single-center, randomized, open-label, parallel-arm, 3-period crossover study conducted in healthy white (Caucasian) men."( Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
Bramer, SL; Bricmont, P; Shoaf, SE; Zimmer, CA, 2007
)
0.34

Compound-Compound Interactions

Arginine vasopressin (AVP) in combination with norepinephrine (NE) can "buy" time for the subsequently definitive treatment of traumatic hemorrhagic shock.

ExcerptReferenceRelevance
"The present study was designed to evaluate the effect of conventional fluid resuscitation and small volume resuscitation alone and combined with arginine vasopressin (AVP) on cerebral perfusion pressure (CPP) and protein S100B during experimental haemorrhagic shock."( Release of protein S100B in haemorrhagic shock: effects of small volume resuscitation combined with arginine vasopressin.
Bein, B; Cavus, E; Dörges, V; Meybohm, P; Scholz, J; Stadlbauer, KH; Steffen, M; Weber, B; Wenzel, V, 2008
)
0.35
" Following haemodynamic decompensation, pigs received either (1) a combination of crystalloid (40 mL kg(-1)) and colloid (20 mL kg(-1)) solutions (fluid, n=10), (2) hypertonic-hyperoncotic solution (HHS; 4 mL kg(-1)) combined with normal saline (HHS+NS; n=10) or (3) HHS combined with AVP (0."( Release of protein S100B in haemorrhagic shock: effects of small volume resuscitation combined with arginine vasopressin.
Bein, B; Cavus, E; Dörges, V; Meybohm, P; Scholz, J; Stadlbauer, KH; Steffen, M; Weber, B; Wenzel, V, 2008
)
0.35
" With uncontrolled hemorrhagic shock rats, we investigated if arginine vasopressin (AVP) in combination with norepinephrine (NE) is independent (or slightly dependent) of fluid resuscitation and can "buy" time for the subsequently definitive treatment of traumatic hemorrhagic shock in the present study."( Small doses of arginine vasopressin in combination with norepinephrine "buy" time for definitive treatment for uncontrolled hemorrhagic shock in rats.
Lan, D; Li, T; Liu, L; Peng, X; Tian, K; Wu, Y; Xue, M; Zhu, Y, 2013
)
0.39
" The objective of the present study was to investigate whether hypotensive resuscitation in combination with arginine vasopressin (AVP) can prolong the hypotensive resuscitation time by minimizing blood loss and stabilizing hemodynamics for uncontrolled hemorrhagic shock."( Hypotensive resuscitation in combination with arginine vasopressin may prolong the hypotensive resuscitation time in uncontrolled hemorrhagic shock rats.
Hu, Y; Li, T; Liu, L; Peng, X; Yang, G; Zang, J; Zhu, Y, 2015
)
0.42
"With an established rat model of uncontrolled hemorrhagic shock, we compared the beneficial effects of hypotensive resuscitation in combination with AVP to maintain blood pressure at 50 mm Hg for 3 hours to hypotensive resuscitation alone on animal survival, blood loss, and vital organ functions."( Hypotensive resuscitation in combination with arginine vasopressin may prolong the hypotensive resuscitation time in uncontrolled hemorrhagic shock rats.
Hu, Y; Li, T; Liu, L; Peng, X; Yang, G; Zang, J; Zhu, Y, 2015
)
0.42
"Hypotensive resuscitation in combination with AVP maintenance for 3 hours significantly reduced total blood loss and fluid requirement during hypotensive resuscitation period and significantly improved the survival of shock rats as compared with hypotensive resuscitation alone."( Hypotensive resuscitation in combination with arginine vasopressin may prolong the hypotensive resuscitation time in uncontrolled hemorrhagic shock rats.
Hu, Y; Li, T; Liu, L; Peng, X; Yang, G; Zang, J; Zhu, Y, 2015
)
0.42
"Hypotensive resuscitation in combination with early application of AVP could prolong the tolerance time of hypotensive resuscitation and "buy" longer safe prehospital transport time by reducing blood loss and stabilizing hemodynamics."( Hypotensive resuscitation in combination with arginine vasopressin may prolong the hypotensive resuscitation time in uncontrolled hemorrhagic shock rats.
Hu, Y; Li, T; Liu, L; Peng, X; Yang, G; Zang, J; Zhu, Y, 2015
)
0.42
"To observe the clinical efficacy of acupuncture combined with auricular point sticking for menstrual headache and to discuss its mechanism."( [Efficacy of acupuncture combined with auricular point sticking on the content of serum prostaglandin F2α, and plasma arginine vasopressin in patients with menstrual headache].
Gao, F; Li, W; Li, X; Liang, Y; Liu, L; Ma, H; Sun, L; Xu, X, 2015
)
0.42
" The observation group was treated with body acupuncture combined with auricular point sticking and the control group was treated with flunarizine hydrochloride capsules orally."( [Efficacy of acupuncture combined with auricular point sticking on the content of serum prostaglandin F2α, and plasma arginine vasopressin in patients with menstrual headache].
Gao, F; Li, W; Li, X; Liang, Y; Liu, L; Ma, H; Sun, L; Xu, X, 2015
)
0.42
"Body acupuncture combined with auricular point sticking achieves positive efficacy for menstrual headache and its mechanism could be related to regulating the abnormal levels of serum PGF2α and plasma AVP."( [Efficacy of acupuncture combined with auricular point sticking on the content of serum prostaglandin F2α, and plasma arginine vasopressin in patients with menstrual headache].
Gao, F; Li, W; Li, X; Liang, Y; Liu, L; Ma, H; Sun, L; Xu, X, 2015
)
0.42
" Data were analysed using the 2R-1T model to characterize the observed exposure-response relationships and drug-drug interaction."( Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction.
Stam, WB; van der Graaf, PH; van Hasselt, JGC; Yamada, A; Yin, A, 2018
)
0.48
"The 2R-1T model can be of relevance to quantitatively characterize the interaction between two drugs that interact via different receptors and a common transducer pathway."( Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction.
Stam, WB; van der Graaf, PH; van Hasselt, JGC; Yamada, A; Yin, A, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" In contrast, bioavailability was significantly increased in all three models from the Polycarbophil suspension in comparison with a solution of the drug in saline."( Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug in the rat.
Bouwstra, JA; Breimer, DD; De Boer, AG; Junginger, HE; Kok, W; Lehr, CM; Tukker, JJ; Verhoef, JC, 1992
)
0.28
" AVP is well absorbed when applied subcutaneously."( The influence of arginine-vasopressin on stool output and gastrointestinal transit time in healthy volunteers.
Fiedler, F; Klauser, AG; Mühldorfer, BE; Müller-Lissner, SA; Voderholzer, WA, 1995
)
0.29
"A pharmacokinetic study was carried out to assess the bioavailability of desglycinamide-[Arg8]vasopressin (DGAVP, Org 5667)."( Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects.
Hijman, R; Laczi, F; Van Ree, JM; Westenberg, HG; Wiegant, VM, 1994
)
0.29
"The bioavailability from the gastrointestinal tract of peptides as large as nonapeptides is very low, which may be attributed to extensive lumenal and mucosal degradation."( Metabolism of vasopressin, oxytocin, and their analogues in the human gastrointestinal tract.
Fjellestad-Paulsen, A; Lundin, S; Söderberg-Ahlm, C, 1995
)
0.29
"A novel method of assessing the extent of oral bioavailability of arginine-vasopressin (AVP) from pharmacological data was presented."( Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
Iwanaga, K; Kakemi, M; Miyazaki, M; Morimoto, K; Nishide, T; Sawada, S, 2000
)
0.31
" Although it has to be mentioned that the conclusion which can be drawn is limited, the bioavailability of the compounds could be different as well."( Glutamate agonists activate the hypothalamic-pituitary-adrenal axis through hypothalamic paraventricular nucleus but not through vasopressinerg neurons.
Makara, GB; Mergl, Z; Zelena, D, 2005
)
0.33
" Oral administration of RB150 in conscious DOCA-salt rats inhibited brain aminopeptidase A activity, resulting in values similar to those obtained with the brains of normotensive rats, demonstrating the central bioavailability of RB150."( Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension.
Balavoine, F; Bodineau, L; Fassot, C; Frugière, A; Inguimbert, N; Llorens-Cortes, C; Marc, Y; Roques, B, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

vasopressin (SK&F 100273), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-(O-methyl)tyrosine,4-valine,8-arginine]vasopressin (SK & F 101926) and [1)-D-phenylalanine.

ExcerptRelevanceReference
" The functional contributions to, and interactions with, phenolic hydroxyl and aromatic groups as well as basicity in positions 2, 3 and 8, respectively, to or with hormone-receptor affinity and intrinsic (contractile) activity, were determined by analyzing the dose-response curves of five vasopressin peptides lacking one or more of these functional groups."( Dose-response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: possible evidence for regional differences in vasopressin receptor sites within a mammal.
Altura, BM, 1975
)
0.25
" Vasotocin was the most active of the compounds studied and, unlike the vasopressins, its dose-response relationships closely resembled those of hypothalamic extracts."( The use of corticotrophin production by adenohypophysial tissue in vitro for the detection and estimation of potential corticotrophin releasing factors.
Buckingham, JC; Hodges, JR, 1977
)
0.26
" Dose-response relationships have been obtained for the attenuation of puromycin-induced amnesia in mice by selected neurohypophyseal peptides."( Dose-response relationships in attenuation of puromycin-induced amnesia by neurohypophyseal peptides.
Flexner, JB; Flexner, LB; Hoffman, PL; Walter, R, 1977
)
0.26
" A dose-response relationship was obtained for several parameters and a dosage of 17."( Effects of arginine vasopressin on capillary filtration in the cat ileum.
Granger, DN; Quillen, EW; Taylor, AE, 1977
)
0.26
" Phenoxybenzamine also blocked the response to NA but a dose-response relationship was not apparent."( Effect of intraventricular administration of noradrenaline on water diuresis in goats.
Peeters, G; Vandeputte-Van Messon, G, 1975
)
0.25
" Moreover, a dose-response relationship up to 10 microM was revealed."( Oxytocin at physiological concentrations evokes adrenocorticotropin (ACTH) release from corticotrophs by increasing intracellular free calcium mobilized mainly from intracellular stores. Oxytocin displays synergistic or additive effects on ACTH-releasing
Dayanithi, G; Föhr, KJ; Gratzl, M; Link, H, 1992
)
0.28
" Blood vessels were measured and dose-response curves to different agents tested."( Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients.
Deng, LY; Larochelle, P; Schiffrin, EL, 1992
)
0.28
" The AVP antagonist in the reduced dosage given alone had no effect on hormone levels."( The role of vasopressin in the nicotine-induced stimulation of ACTH and cortisol in men.
Bähr, V; Hader, O; Hensen, J; Oelkers, W; Scherer, G; Stalke, J,
)
0.13
" The dose-response curve for AVP was shifted to the right in parallel by OPC-31260 but not by OPC-21268."( Potent antagonistic action of OPC-31260, a vasopressin V2 receptor antagonist, on [Arg8]vasopressin-induced vasoconstriction in isolated simian femoral arteries.
Chiba, S; Tsukada, M, 1992
)
0.28
" Dose-response curves showed that the rank order of potency for stimulation of production of inositol phosphates was AVP > ET-1 > PGF2 alpha, similar to the sensitivity of blood vessels to these agents."( Inositol phosphate production in response to [Arg8]vasopressin, endothelin 1, and prostaglandin F2 alpha in rat aorta and mesenteric arteries.
Nguyen, PV; Parent, A; Schiffrin, EL; Yang, XP, 1992
)
0.28
" The development of a fast-release oral dosage form for peptide drugs on the basis of Polycarbophil appears to be possible."( Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug in the rat.
Bouwstra, JA; Breimer, DD; De Boer, AG; Junginger, HE; Kok, W; Lehr, CM; Tukker, JJ; Verhoef, JC, 1992
)
0.28
" This was seen as a 5-6-fold right shift in the dose-response curves for AVP action (cAMP accumulation in intact cells and AC stimulation in homogenates and isolated membranes) and in a decrease in the maximum effect of AVP on these parameters."( Desensitization of the human V2 vasopressin receptor. Homologous effects in the absence of heterologous desensitization.
Antaramian, A; Birnbaumer, M; Gilbert, S; Themmen, AP, 1992
)
0.28
" Intracerebroventricular injection (ICV) of AVP exacerbated the ischemic cortical edema and it showed dose-response correlation."( [An experimental study of arginine vasopressin on acute ischemic brain edema in gerbils (1)].
Liu, X, 1992
)
0.28
" To define the relationships between respiratory failure, cardiovascular collapse, and death, respiratory and cardiovascular parameters were monitored in anesthetized rats following the intravenous administration of SK&F 101926 at a dosage (3 mg/kg) which resulted in 70% mortality."( Respiratory and cardiovascular changes associated with toxic doses of a peptide antagonist of vasopressin in the rat.
Joran, ME; Murphy, DJ, 1992
)
0.28
" Arterial pressure dose-response effects of phenylephrine, angiotensin II, and vasopressin were similar between renal-wrapped and sham-operated animals; however, cardiac baroreceptor reflex sensitivity was suppressed in the hypertensive rats."( Sympathetic nervous system in high sodium one-kidney, figure-8 renal hypertension.
Guerra, P; Haywood, JR; Hinojosa-Laborde, C, 1992
)
0.28
" Insulin (1 and 100 mU/ml) shifted AVP dose-response curves to the right, reducing relative potency of AVP by 16-fold and 220-fold, respectively."( Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells.
Ram, JL; Sowers, JR; Standley, PR; Zemel, MB; Zhang, F, 1991
)
0.28
" Administration of nifedipine to Sprague-Dawley and WKY rats did not affect the dose-response curve to AVP, but nifedipine administration in SHR led to a significant inhibition of the pressor responses to AVP."( Pressor actions of arginine vasopressin in pithed Sprague-Dawley, Wistar-Kyoto and spontaneously hypertensive rats before and after treatment with nifedipine or pertussis toxin.
Tabrizchi, R; Triggle, CR, 1991
)
0.28
" Pretreatment with dexamethasone for 48 hours shifted the dose-response trisphosphate curves of angiotensin II- and arginine vasopressin-induced inositol trisphosphate production to the left, that is, it significantly reduced the half-maximal effective concentrations of angiotensin II (from 25 nM to 5 nM) and arginine vasopressin (from 50 nM to 25 nM)."( Potentiation of inositol trisphosphate production by dexamethasone.
Iwaita, Y; Kato, H; Nakazato, Y; Saruta, T; Sato, A; Suzuki, H, 1992
)
0.28
" Dose-response curves were constructed for phenylephrine (an alpha 1-adrenergic agonist), ST-91 (an alpha 2-adrenergic agonist), angiotensin II, and arginine vasopressin (AVP)."( Does magnesium sulfate alter the maternal cardiovascular response to vasopressor agents in gravid ewes?
Chatterjee, P; Chestnut, DH; Sipes, SL; Thompson, CS; Vincent, RD; Weiner, CP, 1991
)
0.28
"Intra-arterially infused arginine vasopressin (AVP) elevated systemic blood pressure (BP) in the Sprague-Dawley rat according to a dose-response pattern while cochlear blood flow (CoBF), as measured by laser Doppler flowmetry, was elevated only at the highest dose."( The influence of intra-arterial infusion of arginine vasopressin on cochlear blood flow in the rat.
Coleman, JK; Dengerink, HA; McLaren, GM; Quirk, WS; Wright, JW, 1991
)
0.28
" The dose-response relation with AVP thus shifted to the right."( Inhibition by phorbol ester of cellular adenosine 3',5'-monophosphate production and cellular free calcium mobilization in response to arginine vasopressin in rat renal papillary collecting tubule cells in culture.
Ishikawa, S; Saito, T, 1991
)
0.28
" Cai changes stimulated by angiotensin-II (Ang-II) show a complex dose-response pattern, with high concentrations (greater than or equal to 1 nM) of Ang-II eliciting a peak-plateau signal and lower doses (0."( Kinetics of cytosolic calcium and aldosterone responses in rat adrenal glomerulosa cells.
Enyedi, P; Quinn, SJ; Tillotson, DL; Williams, GH, 1991
)
0.28
" In the dosage and route of administration used, AVP was found to be a specific ACTH secretagogue."( Human anterior pituitary response to exogenous arginine vasopressin.
Gehris, TL; Kathol, RG; Lewis, DA; Meller, WH, 1991
)
0.28
" Dose-response curves for methoxamine and vasopressin were not significantly different between groups."( Does enhanced sympathetic tone contribute to angiotensin II hypertension in rats?
Chow, KY; Kline, RL; Mercer, PF, 1990
)
0.28
" In abdominal aortic rings from both groups of animals, cumulative dose-response curves to PE and AVP were completed in 21 and 3% O2 conditions."( Attentuation of systemic vasoreactivity in chronically hypoxic rats.
Doyle, MP; Walker, BR, 1991
)
0.28
"05) of both the vasopressin-urine osmolality and the vasopressin-urine flow dose-response curves."( Effect of cyclo-oxygenase blockade on the renal actions of vasopressin and SK&F 105494 in the rhesus monkey.
Albrightson-Winslow, CR; Brooks, DP; Caldwell, NC; Kinter, LB; Koster, PF, 1990
)
0.28
" The dose-response relation shifted to the right."( Prompt inhibition of arginine vasopressin-induced cellular adenosine 3',5'-monophosphate production by extracellular sodium depletion in rat renal inner medullary collecting duct cells in culture.
Ishikawa, SE; Okada, K; Saito, T, 1990
)
0.28
" Cumulative dose-response curves were generated for KCl (5-100 mM), NE (10(-10)-10(-5) M), AVP, and AVT (both 10(-10)-10(-6) M) in the presence and absence of a selective V1 vasopressinergic inhibitor, [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid), 2-(O-methyl)tyrosine]arginine vasopressin ([d(CH2)5Tyr(Me)]AVP)."( Ontogeny of vasoconstrictor neurohypophysial hormone function in rats.
Balaraman, V; Claybaugh, JR; Ichimura, WM; Kullama, LK; Nakamura, KT, 1990
)
0.28
" We compared the dose-response characteristics of OT and AVP by the in vitro cumulative dose-response curve technique."( Oxytocin- and vasopressin-binding sites in the rat uterus: competition binding and inhibitory pA2 studies with oxytocin and oxytocin antagonists.
Cao, L; Chan, WY; Hill, PS; Hruby, VJ, 1990
)
0.28
"The objective of the study was to determine dose-response relationships of growth hormone, vasopressin, blood pressure, heart rate, and behavioral responses to clonidine."( Dose-response profiles of plasma growth hormone and vasopressin after clonidine challenge in man.
Allen, D; Brown, GM; Cleghorn, JM; Mazurek, M; Szechtman, B, 1990
)
0.28
" Eight of the ten patients experienced cardiac arrest within 48 h (range 6-87 h) despite the rather large dosage of epinephrine."( Long-term renal preservation after brain death maintained with vasopressin and epinephrine.
Kinoshita, Y; Onishi, S; Sugimoto, T; Yahata, K; Yoshioka, T, 1990
)
0.28
" The response delay for Ang II was consistently briefer than that for the same concentration of AVP, showing a 2-3 log unit separation in the dose-response relations."( Cytosolic calcium and aldosterone response patterns of rat adrenal glomerulosa cells stimulated by vasopressin: comparison with angiotensin II.
Enyedi, P; Quinn, SJ; Tillotson, DL; Williams, GH, 1990
)
0.28
" Vasopressin in concentrations as low as 10 pmol/l stimulated a sixfold increase in total inositol phosphates; the dose-response curve was triphasic."( The interaction of arginine vasopressin and oxytocin with bovine adrenal medulla cells.
Nussey, SS; Taylor, AH; Whitley, GS, 1989
)
0.28
" The dose-response curve for the effect of CRF-41 on cAMP production was markedly shifted to the right by dexamethasone acting in the time-domain of fast inhibition (i."( Glucocorticoids act rapidly in vitro to attenuate second messenger responses to ACTH secretagogues in rats.
Gillham, B; Nicholson, SA, 1989
)
0.28
" Both placebo and nifedipine dosed during the continued water deprivation and stabilized urinary osmolarity condition caused an increase in the urinary excretions of solutes."( Effect of nifedipine on urinary concentrating ability: a placebo controlled study.
Iizuka, T; Ishizaki, T; Okaniwa, T; Yasuda, K, 1989
)
0.28
" In a separate group of conscious rats, it was determined that AVPRA (1-100 mg/kg/hr) produced a dose-dependent, parallel and rightward shift in the AVP vasopressor dose-response curve: the highest dose of AVPRA (i."( Effect of a selective V1 vasopressin receptor antagonist on the sequelae of endotoxemia in the conscious rat.
Egan, JW; Jugus, M; Kinter, LB; Lee, K; Smith, EF, 1989
)
0.28
" 259 in the PM); and, sensitivity of the ACTH dose-response curve (first significant increase in ACTH with 1 IU of vasopressin in the AM but not significant even after 3 IU in the PM)."( Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. In vivo bioassay of corticotropin-releasing factor (CRF) which provides evidence for CRF mediation of the diurnal rhythm of ACTH.
Jarrett, DB; Robinson, AG; Salata, RA; Verbalis, JG, 1988
)
0.27
"A multi-column perifusion system was used to investigate the dynamics of the dose-response relationships of ACTH release by ovine pituitary cells when stimulated by both corticotrophin-releasing hormone (CRF) and arginine vasopressin (AVP) given alone and in combination."( Characteristics of the ACTH response to repeated pulses of corticotrophin-releasing factor and arginine vasopressin in vitro.
Brett, JT; Donald, RA; Evans, MJ; Livesey, JH; McIntosh, JE; McIntosh, RP; McLay, JL, 1988
)
0.27
" Decreasing [Mg2+]0 from the optimal concentration of 1 to 0 mM caused a 20-fold parallel rightward displacement of the oxytocin dose-response curve."( Magnesium ions and oxytocin sensitivity of the male mouse anococcygeus.
Gibson, A, 1985
)
0.27
" Log dose-response curves were obtained for different doses of arginine-vasopressin (AVP), arginine-vasotocin (AVT), mesotocin (MT), oxitocin (OT) and ovine CRF (oCRF) and compared to the response obtained with dilutions of duck median eminence extracts (DME)."( The regulation of the corticomelanotropic cell activity in Aves--II. Effect of various peptides on the release of ACTH from dispersed, perfused duck pituitary cells.
Castro, MG; Estivariz, FE; Iturriza, FC, 1986
)
0.27
" Log dose-response curves were obtained for all the peptides ranging from 5 to 100 ng/ml."( The regulation of the corticomelanotropic cell activity in aves. III--Effect of various peptides on the release of MSH from dispersed, perfused duck pituitary cells. Cosecretion of ACTH with MSH.
Castro, MG; Estivariz, FE; Iturriza, FC, 1988
)
0.27
" Dose-response curves were established for AVP and flank marking in the presence or absence of different concentrations of each antagonist."( Inhibition of vasopressin-stimulated flank marking behavior by V1-receptor antagonists.
Albers, HE; Ferris, CF; Meenan, DM; Singer, EA, 1988
)
0.27
" The slopes of the dose-response lines of CRF-41 were greater than those of AVP, less than those of hypothalamic extracts from control animals and resembled those of hypothalamic extracts from Brattleboro rats."( Two distinct corticotrophin releasing activities of vasopressin.
Buckingham, JC, 1985
)
0.27
" In dose-response experiments, the minimum concentration of CRF in a 10-min pulse required to significantly raise the output of ACTH was 200 pM, and initial responses had not attained maximal levels with concentrations of CRF increased to 2 microM."( The effect of various corticotropin-releasing factor trains on the release of adrenocorticotropin, beta-endorphin, and beta-lipotropin from perifused ovine pituitary cells.
Brett, JT; Donald, RA; Evans, MJ; Livesey, JH; McIntosh, JE; McIntosh, RP; Roud, HK, 1985
)
0.27
" The comparison of their dose-response curves indicated that two different mechanisms are involved in the release of ACTH by neurohypophysial peptides and their analogs."( Analysis of the dual mechanism of ACTH release by arginine vasopressin and its analogs in conscious rats.
Dantzer, R; LeMoal, M; Mormède, P, 1985
)
0.27
" Dose-response studies showed that the effect on gonadotropin secretion occurred at concentrations of 8-bromo-cyclic adenosine monophosphate two orders of magnitude lower than those affecting adrenocorticotropic hormone secretion."( Corticotropin-releasing factor can stimulate gonadotropin secretion by human fetal pituitaries in superfusion.
Blumenfeld, Z; Jaffe, RB; Kuhn, RW, 1986
)
0.27
" Dose-response curves for the alpha-adrenergic action of adrenaline or glucagon applied in the presence of increasing doses of glucagon or adrenaline showed that each hormone increases the maximal response to the other without affecting its ED50."( Effect of cyclic AMP-dependent hormones and Ca2+-mobilizing hormones on the Ca2+ influx and polyphosphoinositide metabolism in isolated rat hepatocytes.
Claret, M; Mauger, JP; Poggioli, J, 1986
)
0.27
" Dose-response measurements indicate that the potentiation of Ca2+ influx by glucagon occurs even at low (physiological) concentrations of the hormone."( Synergistic stimulation of Ca2+ uptake by glucagon and Ca2+-mobilizing hormones in the perfused rat liver. A role for mitochondria in long-term Ca2+ homoeostasis.
Altin, JG; Bygrave, FL, 1986
)
0.27
"The time-course and dose-response of the in-vivo secretion of aldosterone and corticosterone after administration of ACTH(1-24) were measured in adrenal venous blood from female Brattleboro rats, homozygous for hypothalamic diabetes insipidus and lacking arginine vasopressin (AVP)."( Release of aldosterone and corticosterone from the adrenal cortex of the Brattleboro rat in response to administration of ACTH.
Brudieux, R; Krifi, MN; Laulin, JP, 1986
)
0.27
" Dose-response studies indicate that at low doses (less than 20 micrograms) EGF is as potent a stimulus for ACTH release as CRF."( Epidermal growth factor acts as a corticotropin-releasing factor in chronically catheterized fetal lambs.
Ervin, MG; Fisher, DA; Lam, RW; Padbury, JF; Polk, DH; Reviczky, AL, 1987
)
0.27
" The vasopressin analogs [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-(O-methyl)tyrosine,8-arginine]vasopressin (SK&F 100273), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-(O-methyl)tyrosine,4-valine,8-arginine]vasopressin (SK&F 100501), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-D-tyrosine,4-valine,8-arginine]vasopressin (SK&F 100885), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-(O-ethyl)tyrosine,4-valine,8-arginine]vasopressin (SK&F 100398), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-D-isoleucine,4-valine,8-arginine]vasopressin (SK&F 101485), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-(O-ethyl)-tyrosine,4-valine,8-arginine]vasopressin (SK&F 101498), [1-(beta-mercapto-beta,beta-cyclopentamethylene propionic acid),2-(O-ethyl)D-tyrosine,4-valine,8-arginine,9-desglycine]vasop ressin (SK&F 101926) and [1-(beta-mercapto-beta-beta-cyclopentamethylene propionic acid),2-D-phenylalanine,4-valine,8-arginine] vasopressin (SK&F 101071) antagonized arginine vasopressin-stimulated water flux and displaced the agonist dose-response relationship to the right in a parallel fashion."( Mechanism of action and structural requirements of vasopressin analog inhibition of transepithelial water flux in toad urinary bladder.
Huffman, W; Kinter, LB; Mann, WA; Stassen, F, 1986
)
0.27
" In water diuretic dogs, SK&F 104146 and 105494 shifted the vasopressin dose-response for antidiuresis to the right."( SK&F 105494: a potent antidiuretic hormone antagonist devoid of partial agonist activity in dogs.
Albrightson-Winslow, C; Brickson, B; Brooks, DP; Caldwell, N; Huffman, WF; Kinter, LB; Stassen, FL, 1988
)
0.27
"The dosage form (drop or spray) and site of administration (dorsal or ventral surface of the nostril) profoundly affect the distribution and clearance of a gamma-emitting 99mTc-labeled diethylenetriamine pentaacetic acid (99mTc-DTPA) solution in dogs."( Nasal delivery of a vasopressin antagonist in dogs.
Kinter, LB; Liversidge, GG; Sternson, WL; Wilson, CG, 1988
)
0.27
" AVP treatment of Leydig cells for 72 h led to a significant and dose-dependent reduction in the hCG-responsiveness without altering the slope of the hCG dose-response curve."( Time-related effects of arginine vasopressin on steroidogenesis in cultured mouse Leydig cells.
Pointis, G; Tahri-Joutei, A, 1988
)
0.27
" Dose-response curves for either peptide were not altered in the presence of the antagonist to the other peptide; however, they were shifted to the left in the RHT hamsters."( Specificity of arginine vasopressin and angiotensin II for microvessels in the hamster cheek pouch after the induction of renovascular hypertension.
Gilmore, JP; Joyner, WL; Mohama, RE, 1988
)
0.27
" Calculation of the ED50 data from dose-response curves of both peptides show that AVP is about 10(4)-fold more active than OXT in inhibiting in vitro progesterone and androstenedione secretion."( Inhibitory effect of oxytocin and vasopressin on steroid release by cultured porcine luteal cells.
Jarry, H; Pitzel, L; Probst, I; Wuttke, W, 1988
)
0.27
" A specific V1, receptor AVP antagonist [d(CH2)5Tyr(Me)AVP] produced no fall in blood pressure but returned the noradrenaline dose-response curve to normal."( Selective renal medullary damage and hypertension in the rat: the role of vasopressin.
Bing, RF; Forsling, ML; Godfrey, NP; Russell, GI; Swales, JD; Thurston, H, 1986
)
0.27
" The differences in pattern and intensity of staining due to increasing the dosage rate of the in vivo vasopressin treatment, might mean that the current procedure retains preferentially either low or high affinity populations of binding sites depending on the implanted dose."( Immunocytochemically-stained vasopressin binding sites in rat brain. Ventricular application of vasopressin/Accurel in the Brattleboro rat.
Boer, GJ; Ravid, R; Swaab, DF; Van der Woude, TP, 1986
)
0.27
" Dose-response relationships were studied at 9 +/- 1, 25 +/- 1, 75 +/- 3, 303 +/- 15, and 817 +/- 42 pg AVP/ml."( Direct cardiac effects of vasopressin and their reversal by a vascular antagonist.
Boyle, WA; Segel, LD, 1986
)
0.27
" Dose-response curves indicated that there was a similar enhancement in pressor sensitivity to AVP, ANG II, and PE in the absence of the baroreceptors."( Cardiovascular actions of vasopressin: baroreflex modulation in the conscious rat.
Cowley, AW; Osborn, JW; Webb, RL, 1986
)
0.27
" A dose-response curve to NE, ANG II, and lysine vasopressin was also performed."( Angiotensin II, vasopressin, and sympathetic activity in conscious rats with endotoxemia.
Brunner, HR; Nussberger, J; Schaller, MD; Waeber, B, 1985
)
0.27
"Arginine-8-vasopressin (AVP) was injected into the cerebral ventricles of rats in order to characterize the dose-response relations of the convulsant actions of AVP and to obtain a detailed description of other acute behavioural effects."( Abnormal behavioural changes associated with vasopressin-induced barrel rotations.
Boakes, RJ; Ednie, JM; Edwardson, JA; Keith, AB; Sahgal, A; Wright, C, 1985
)
0.27
" Dose-response measurements with AVP-A showed ED50 values of 76 and 62 nM for PA and PI labeling, respectively."( Vasopressin rapidly stimulates phosphatidic acid-phosphatidylinositol turnover in rat anterior pituitary cells.
Labrie, F; Leung, PC; Raymond, V; Veilleux, R, 1985
)
0.27
" A dose-response study in five of the patients indicated that peroral DDAVP doses as small as 10 micrograms have effects on renal concentrating ability."( Peroral treatment of diabetes insipidus with a polypeptide hormone analog, desmopressin.
Hammer, M; Vilhardt, H, 1985
)
0.27
" AVP was found to stimulate urea synthesis and the dose-response curve suggests that such an effect is present at concentrations of the hormone as low as 25-50 pmol/l."( The effect of arginine vasopressin on ureagenesis in isolated rat hepatocytes.
Cohen, RD; Drew, PJ; Evans, SJ; Iles, RA; Metcalfe, HK; Monson, JP, 1985
)
0.27
" The dose-response curves with intraarterial vasopressin were shifted approximately 100-fold in concentration to the right relative to those with topically suffused vasopressin."( A microcirculatory technique for evaluating intravascular and topical administration of vasoactive agents: response to AVP in the SHR.
Dusseau, JW; Hutchins, PM; Sueta, CA, 1985
)
0.27
" The dose-response curve for vasopressin-stimulated lipogenesis is similar to the dose-response curve for glycogenolysis and release of lactate plus pyruvate."( Stimulation of hepatic lipogenesis and acetyl-coenzyme A carboxylase by vasopressin.
Assimacopoulos-Jeannet, F; Denton, RM; Jeanrenaud, B, 1981
)
0.26
" Dose-response curves to AVP and to oCRF were obtained, and the response to a low dose of oCRF was potentiated by a low dose of AVP."( Effect of hypothalamic neuropeptides on corticotrophin release from quarters of rat anterior pituitary gland in vitro.
Adrian, TE; Bloom, SR; Gillham, B; Jones, MT; Nicholson, SA, 1984
)
0.27
" The antagonist dPVDAVP shifted the dose-response curves to the right without changing their slope."( Hemodynamic effects of antagonists of the vasoconstrictor action of vasopressin in conscious dogs.
Liard, JF; Spadone, JC,
)
0.13
" The time course and the dose-response curve of the kinase activation closely parallel vasopressin's effect on osmotic water flow."( Effect of vasopressin on cyclic AMP-dependent protein kinase in toad urinary bladder.
Franki, N; Schlondorff, D, 1980
)
0.26
" Arginine vasopressin (AVP) stimulated cyclic AMP production both in medullary and cortical cells with a dose-response relationship at concentrations ranging from 10 microU/ml to 10 mU/ml, whereas parathyroid hormone (PTH) and calcitonin did only in the latter."( Altered cyclic AMP responsiveness to vasopressin in rat renal medullary dispersed cells by acute elevation of endogenous vasopressin.
Itabashi, A; Katayama, S; Yamaji, T, 1982
)
0.26
" In addition, an ACTH and corticosteroid dose-response correlation estimated the threshhold ACTH to be 20-30 pg/ml."( Vasopressin, ACTH, and corticosteroids during hypercapnia and graded hypoxia in dogs.
Dallman, MF; Keil, LC; Raff, H; Shinsako, J, 1983
)
0.27
" The dose-response curves for the vasopressin- and angiotensin-stimulated responses lie close to the respective receptor occupation curves, rather than at the lower hormone concentrations needed to evoke activation of glycogen phosphorylase."( Rapid breakdown of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate in rat hepatocytes stimulated by vasopressin and other Ca2+-mobilizing hormones.
Brewster, G; Creba, JA; Downes, CP; Hawkins, PT; Kirk, CJ; Michell, RH, 1983
)
0.27
" In hepatocytes obtained from rats partially hepatectomized 3 days before experiments were performed, the dose-response curves to glucagon were shifted to the right by about two orders of magnitude as compared to those of the control cells."( Sensitivity of liver cells formed after partial hepatectomy to glucagon, vasopressin and angiotensin II.
Corvera, S; García-Saínz, JA; Huerta-Bahena, J; Villalobos-Molina, R, 1983
)
0.27
" Dose-response studies indicated a rank order of CRA as follows: CRF greater than AVP greater than OXY greater than AII = AIII."( Angiotensin II and ACTH release: site of action and potency relative to corticotropin releasing factor and vasopressin.
Negro-Vilar, A; Spinedi, E, 1983
)
0.27
" Two parameters were analyzed from the dose-response curve: pD2 and the relative contractile response compared to the maximal one induced by oxytocin."( Influence of estrogen and progesterone on the uterine sensitivity in vitro to neuropituitary hormones in the Brazilian marsupial Didelphis albiventris: comparison with lactating animals.
Calixto, SL; Ladosky, W, 1984
)
0.27
" A dose-response study revealed a U-shaped relationship for this effect of beta E 2-9 in animals of both sexes."( The stimulatory effect of a non-opiate beta-endorphin fragment on arginine-vasopressin release in rats.
de Wied, D; Laczi, F; Sykes, JE; Wiegant, VM, 1984
)
0.27
" Further studies may be valuable, possibly relating dosage to body weight."( DDAVP in young enuretic patients: a double-blind trial.
Ferrie, BG; Glen, ES; MacFarlane, J, 1984
)
0.27
" DDAVP up to 10(-5) mol/l had no effect but shifted the dose-response curves of AVP to the right."( DDAVP (1-desamino-8-D-arginine vasopressin): an antagonist of the pressor action of endogenous vasopressin?
Derkx, FH; Jones, R; Man in 't Veld, AJ; Reid, JL; Schalekamp, MA, 1983
)
0.27
" Neither repeated daily subcutaneous injections of either Pitressin tannate or VP in oil, continuous peripheral application of VP in various dosage rates using the long-acting Accurel/collodion implantable delivery module, nor daily intracerebroventricular injections of VP in saline, improved postnatal body or brain growth."( Vasopressin fails to restore postnatally the stunted brain development in the Brattleboro rat, but affects water metabolism permanently.
Boer, GJ; Kragten, R; Kruisbrink, J; Swaab, DF,
)
0.13
"The effects of intravenous infusions of the stable prostaglandin analogue 9-deoxo-16,16-dimethyl-9-methylene-PGE2 (9-methylene-PGE2) in a dosage of 10 or 24 micrograms/min were studied in the consicious euhydrated, dehydrated, and hyperhydrated with the simultaneous administration of exogenous arginine vasopressin (AVP), sheep."( The prostaglandin-analogue-9-deoxo-16,16-dimethyl-9-methylene-PGE2 inhibits the antidiuretic effect of vasopressin (AVP) in the conscious sheep.
Bygdeman, M; Christensen, NJ; Greén, K; Jonasson, H; Leksell, LG; Rundgren, M; Vesterqvist, O; Wallin, CJ, 1984
)
0.27
" Data processing consists of mathematical representation of two curved dose-response surfaces followed by solution of this pair of nonlinear simultaneous equations for the unknown arginine vasopressin and desmopressin concentrations."( A bivariate radioimmunoassay for arginine vasopressin and the synthetic antidiuretic agent 1-deamino-8-D-arginine vasopressin (desmopressin).
Dawson, KP; Lynskey, CP; Sadler, WA, 1984
)
0.27
" To test the agent's capacity to block the pressor action of exogenous AVP In humans, we constructed a dose-response curve with AVP doses of 1 to 20 mU/kg, raising BP by up to 30 mm Hg."( Effects of a specific inhibitor of the vascular action of vasopressin in humans.
Gavras, H; Gavras, I; Kohlmann, O; Mulinari, RA; Ramos, O; Ribeiro, AB; Saragoça, M,
)
0.13
" With 2 h CS-US delay the same dosage of the peptide caused CTA impairment, manifested by weaker and faster decaying aversion to saccharin."( Specificity of the effect of desglycinamide (8-D-arginine) deaminovasopressin on short--term memory.
Bures, J; Buresová, O; Skopková, J, 1983
)
0.27
" Nevertheless, the antinociceptive action of vasopressin does not appear to be secondary to its pressor activity, since phenylephrine failed to induce an antinociceptive effect at a dosage that mimicked the pressor response to vasopressin."( Vasopressin-induced antinociception: an investigation into its physiological and hormonal basis.
Berntson, GG; Berson, BS; Kirk, WT; Torello, MW; Zipf, W, 1983
)
0.27
" The log dose-response characteristics of the CRF activities of small-CRF and AVP differed."( Characterization of corticotropin releasing factor (CRF) and arginine vasopressin in median eminence extracts on sephadex gel-filtration.
Aoki, Y; Hashimoto, K; Kageyama, J; Ofuji, T; Ohno, N; Takahara, J; Yunoki, S, 1981
)
0.26
" Hypothalamic extracts from Brattleboro rats stimulated the production of corticotrophin by pituitary segments in vitro but both their potency and the slopes of their dose-response lines were significantly less than those of controls."( The influence of vasopressin on hypothalamic corticotrophin releasing activity in rats with inherited diabetes insipidus.
Buckingham, JC, 1981
)
0.26
" Complete vasopressin/blood pressure dose-response curves were constructed from circulating plasma vasopressin concentrations measured at the end of each infusion."( Effect of acute vasopressin infusion on blood pressure and plasma angiotensin II in normotensive and DOCA-salt hypertensive rats.
Garcia del Rio, C; Hughes, MJ; Morton, JJ, 1982
)
0.26
" The effect of oxytocin on the blood pressure and heart rate was of a lesser magnitude without showing a dose-response relationship."( Blood pressure and heart rate responses to microinjection of vasopressin into the nucleus tractus solitarius region of the rat.
Gordon, FJ; Johnson, AK; Matsuguchi, H; Schmid, PG; Sharabi, FM, 1982
)
0.26
" The duration of the action of sublingually administered DDAVP was 12 hrs; after dosing DVDAVP the effect lasted even 6 hrs."( Effects of vasopressin analogues (DDAVP, DVDAVP) in the form of sublingual tablets in central diabetes insipidus.
Julesz, J; Laczi, F; Lázló, FA; Mezei, G, 1981
)
0.26
" produced a rightward parallel shift of the dose-response curves for AVP in a dose-dependent manner."( OPC-21268 antagonizes arginine vasopressin-induced vasoconstrictor response in the spinally-anesthetized dog.
Chihara, T; Mori, T; Nakamura, S; Onogawa, T; Tominaga, M; Yabuuchi, Y; Yamamura, Y; Yamashita, T, 1995
)
0.29
" Plasma AVP concentrations were not modified by infusion of the lowest dose of PACAP, whereas they were significantly increased in a dose-response fashion when higher amounts of PACAP were given."( Effects of intravenously infused pituitary adenylate cyclase-activating polypeptide on arginine vasopressin and oxytocin secretion in man.
Capretti, L; Chiodera, P; Coiro, V; Volpi, R, 1995
)
0.29
" In series I, five bilaterally adrenalectomized (ADX) adult sheep were maintained on "low" (125 micrograms/h) or "high" (500 micrograms/h) intravenous cortisol replacement, and dose-response curves were obtained with corticotropin-releasing factor (CRF) and arginine vasopressin (AVP)."( Cortisol feedback in adrenalectomized adult sheep.
Coghlan, J; McFarlane, A; Tresham, J; Wintour, EM, 1995
)
0.29
" Dose-response curves to CRF (10, 25, 50, and 100 micrograms/h) and AVP (0."( Corticotropin-releasing factor alone, but not arginine vasopressin alone, stimulates the release of adrenocorticotropin in the conscious intact sheep.
Coghlan, J; McFarlane, A; Tresham, J; Wintour, EM, 1995
)
0.29
" AVP in the dosage given has no major influence on stool output and gastrointestinal transit time in healthy volunteers."( The influence of arginine-vasopressin on stool output and gastrointestinal transit time in healthy volunteers.
Fiedler, F; Klauser, AG; Mühldorfer, BE; Müller-Lissner, SA; Voderholzer, WA, 1995
)
0.29
" Infusion of vasopressin in a dosage sufficient to increase MAP to the basal value resulted in a reduction in VE, a further drop in VO2, and a return to normocapnia."( Metabolic and ventilatory responses to anemic hypoxia in conscious rats.
Matsuoka, T; Mortola, JP; Saiki, C, 1994
)
0.29
" [4-Threonine, 7-glycine]oxytocin, a highly potent and selective uterotonic oxytocin analogue, had no detectable prostaglandin-releasing activity at a dosage 30 times higher than oxytocin."( Agonist and antagonist specificities of decidual prostaglandin-releasing oxytocin receptors and myometrial uterotonic oxytocin receptors in pregnant rats.
Chan, WY; Chen, DL; Manning, M, 1994
)
0.29
"9 nmol/L) independently of the IL-6 dose administered, suggesting that the doses employed were at the top of the dose-response curve for these hormones."( Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion.
Chrousos, GP; Gunn, H; Magiakou, MA; Mastorakos, G; Weber, JS, 1994
)
0.29
" In contrast, combined treatment with enalapril and AVPA resulted in a 36 +/- 11% decrease in blood pressure after epidural dosing (n = 6)."( Endogenous vasopressin and renin-angiotensin systems support blood pressure after epidural block in humans.
Carp, H; Garvey, D; Jayaram, A; Vadhera, R, 1994
)
0.29
" In experiment 3, explants were incubated in the presence of oxytocin or arginine vasopressin at 10(-9) to 10(-6) M to establish dose-response curves for the activation of PLC and release of PGF2 alpha."( Cellular mechanisms mediating the stimulation of ovine endometrial secretion of prostaglandin F2 alpha in response to oxytocin: role of phospholipase C and diacylglycerol.
Brockman, JA; Hayes, SH; Lee, JS; Lowberger, LL; Silvia, WJ; Trammell, DS, 1994
)
0.29
" The dose-response relationship and rate of onset of action of the V1 antagonists (SK&F 100273) were explored."( Etiologic significance of arginine vasopressin in motion sickness.
Cheung, BS; Kinter, LB; Kohl, RL; Money, KE, 1994
)
0.29
" A dose-response relationship between CRH and the hormones measured was found in patients and controls."( Stimulation of the pituitary-adrenal system with graded doses of CRH and low dose vasopressin infusion in depressed patients and healthy subjects: a pilot study.
Gispen-de Wied, CC; Kok, FW; Koppeschaar, HP; Thijssen, JH; van Ree, JM; Westenberg, HG; Wynne, HJ, 1993
)
0.29
" Dose-response curves to CPA were shallower and maximal responses were weaker than those produced by the other agonists."( Interactions of adenosine A1 receptor-mediated renal vasoconstriction with endogenous nitric oxide and ANG II.
Barrett, RJ; Droppleman, DA, 1993
)
0.29
" KCl, phenylephrine (PHE) and arginine-vasopressin (AVP) dose-response curves (DR) were obtained at a preload of 500 mg which allowed the maximum response in control rings."( In vitro femoral arterial responses to vasoconstrictor and vasodilator agents in endotoxin shock.
Baker, CH; Price, JM; Sutton, ET; Zhou, Z, 1994
)
0.29
" important differences are noted in the dose-response of aldosterone secretion to adrenocorticotropin (ACTH), which is often shifted to a lower concentration sensitivity in cultured cells."( A model for studying regulation of aldosterone secretion: freshly isolated cells or cultured cells?
Balestre, MN; Chouinard, L; Gallo-Payet, N; Guillon, G; Payet, MD, 1993
)
0.29
" Cocaine produced a shift to the left of the norepinephrine dose-response in vessels from both controls and hypertensive patients."( Morphology of resistance arteries and comparison of effects of vasoconstrictors in mild essential hypertensive patients.
Deng, LY; Larochelle, P; Schiffrin, EL, 1993
)
0.29
"The effects of human atrial natriuretic peptide (ANP) on glomerular filtration rate (GFR), renal plasma flow (RPF), urinary flow rate, urinary sodium excretion, tubular function estimated by lithium clearance, and plasma levels of sodium and water homeostatic hormones were studied in a dose-response study with 50 healthy subjects."( Dose-response study of atrial natriuretic peptide bolus injection in healthy man.
Eiskjaer, H; Pedersen, EB, 1993
)
0.29
" For AII, reduced vasoactivity with low chloride was evident both in terms of the threshold dose and on the linear part of the dose-response curve but not for the maximum response."( Chloride anion concentration as a determinant of renal vascular responsiveness to vasoconstrictor agents.
Lin, YS; McGiff, JC; Quilley, CP, 1993
)
0.29
" Both the time-effect and dose-response relationships of AVP-induced changes in HR and CT were biphasic."( Differential effects of centrally injected AVP on heart rate, core temperature, and behavior in rats.
De Wied, D; Diamant, M, 1993
)
0.29
" Unilateral intratesticular injection of 10 micrograms naloxone led to a dose-dependent increase in the hCG-responsiveness without altering the slope of the hCG dose-response curve."( Local regulation of testicular immunoreactive-arginine vasopressin and steroidogenesis by naloxone.
Allevard, AM; Bedin, M; Fillion, C; Gharib, C; Huges, JN; Pointis, G; Tahri-Joutei, A, 1993
)
0.29
" Dose-response assessment indicated that 3 mg/kg was the optimal dose for peripherally administered (IP) OT on the elevated plus-maze."( An anxiolytic action of oxytocin is enhanced by estrogen in the mouse.
Brooks, PJ; Goldman, D; McCarthy, MM; McDonald, CH, 1996
)
0.29
" We examined the dose-response of salt transport, as measured by the lumen-to-bath 22Na+ flux (J1 --> b) and transepithelial voltage (VT), and of osmotic water permeability (Pf), to AVP in isolated perfused cortical collecting ducts (CCDs) from three groups of rats: (1) implanted with a 1 mg d-aldosterone pellet, which produced a moderately elevated, but physiologically relevant, plasma aldosterone concentration of 18."( AVP and aldosterone at physiological concentrations have synergistic effects on Na+ transport in rat CCD.
Hawk, CT; Li, L; Schafer, JA, 1996
)
0.29
"Dose-response characteristics of the uterotonic action of oxytocin and arginine vasopressin were compared and analyzed by the in vitro cumulative dose-response curve technique."( The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists.
Chan, WY; Manning, M; Wo, NC, 1996
)
0.29
"The uterotonic dose-response curves for oxytocin and arginine vasopressin were parallel and had the same maximal response."( The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists.
Chan, WY; Manning, M; Wo, NC, 1996
)
0.29
"The parallel dose-response curves for oxytocin and arginine vasopressin suggest that the uterotonic action of vasopressin is also mediated by the oxytocin receptor."( The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists.
Chan, WY; Manning, M; Wo, NC, 1996
)
0.29
" The dose-response curve was bell-shaped."( Pituitary adenylate cyclase-activating polypeptide protects rat-cultured cortical neurons from glutamate-induced cytotoxicity.
Hirai, A; Morio, H; Saito, Y; Tamura, Y; Tatsuno, I, 1996
)
0.29
" We speculate that the lack of a simple, linear dose-response effect of progesterone on blood pressure and baroreflex sensitivity can be explained by progesterone action at multiple receptor populations."( Progesterone rapidly reduces arterial pressure in ewes.
Keller-Wood, M; Roesch, DM, 1997
)
0.3
" All three peptides increased plasma insulin and glucagon concentrations, but their dose-response relationships revealed differences between them."( Effects of oxytocin, arginine-vasopressin and lysine-vasopressin on insulin and glucagon secretion in sheep.
Hyun, HS; Ito, M; Kamita, H; Mineo, H; Muto, H; Onaga, T; Yanaihara, N,
)
0.13
" We performed dose-response studies of recombinant human IL-6 on pituitary hormone secretion in 15 healthy male volunteers, using 5 single, escalating subcutaneous doses of IL-6 (0."( Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure.
Chrousos, GP; Defensor, R; Kyrou, I; Mitsiadis, CS; Papanicolaou, DA; Tsigos, C, 1997
)
0.3
"Thirteen healthy control subjects were investigated on two separate occasions in a placebo controlled, randomized, dose-response study of the effect of intravenous infusion of prostacyclin (PGI2, Flolan, 2, 4 and 8 ng kg(-1) min(-1))."( Effects of prostacyclin on renal haemodynamics, renal tubular function and vasoactive hormones in healthy humans. A placebo-controlled dose-response study.
Bech, JN; Nielsen, CB; Pedersen, EB, 1997
)
0.3
" The changes ensued already after 1 wk of dosing and were first localized in the inner MCDs."( Serotonin (5-HT1A-receptor) agonist-induced collecting duct vacuolation and renal papillary necrosis in the rat.
Bomhard, EM; Hildebrand, H; Leser, KH; Loof, I; Rinke, M; Ruehl-Fehlert, C,
)
0.13
" The ACTH release was gradually increased by CGRP concentrations lower than 10(-10) M, and was decreased at concentrations higher than 10(-9) M, presenting a bell-shaped dose-response curve."( Stimulatory effect of calcitonin gene-related peptide on adrenocorticotropin release from rat anterior pituitary cells.
Iino, K; Iwabuchi, M; Oki, Y; Ozawa, M; Tominaga, T; Watanabe, F; Yoshimi, T, 1998
)
0.3
" Measurement of intracellular cAMP levels revealed that in the case of PTH and AVP, the dose-response curve for the increase in cAMP virtually matched that for transcellular Ca2+ transport."( Hormone-stimulated Ca2+ reabsorption in rabbit kidney cortical collecting system is cAMP-independent and involves a phorbol ester-insensitive PKC isotype.
Bindels, RJ; De Pont, JJ; Hoenderop, JG; Willems, PH, 1999
)
0.3
"01 mg/kg), which by itself decreased arterial pressure only in the Hiroshima rats, the dose-response curve for [Arg8]-vasopressin was much more greatly shifted to the right in the control rats."( Effects of exogenous [Arg8]-vasopressin on borderline-hypertensive Hiroshima rats.
Kumazaki, T; Ozono, R; Teranishi, Y; Tsuru, H, 1999
)
0.3
" Dose-response data show dexmedetomidine to be the most potent inhibitor."( Inhibition of water permeability in the rat collecting duct: effect of imidazoline and alpha-2 compounds.
Hébert, CA; Kudo, LH; Rouch, AJ, 1999
)
0.3
" In contrast, the dose-response curve of the adrenergic agonist phenylephrine was significantly attenuated for the estradiol-replaced rats compared with the ovariectomized group (EC(50)=0."( Effect of estrogen replacement on vasoconstrictor responses in rat mesenteric arteries.
Davidge, ST; Zhang, Y, 1999
)
0.3
"7, n=10 ears), the area increased significantly in the VP dosage of 400 and 1000 microU/kg/min (Bonferroni's method, P<0."( Endolymphatic hydrops induced by chronic administration of vasopressin.
Kakigi, A; Kitano, H; Okada, T; Takeda, S; Takeda, T, 2000
)
0.31
" From these results, we concluded that oral bioavailability of AVP was reasonably predicted by the PK-PD model, provided that appropriate pharmacological effects and appropriate intravascular dosing rate as a reference formulation are available."( Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
Iwanaga, K; Kakemi, M; Miyazaki, M; Morimoto, K; Nishide, T; Sawada, S, 2000
)
0.31
" Pharmacokinetic and dose-response studies suggested that an oral dose of 20 mg/kg was optimal for behavioral and endocrine effects."( Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.
Atkinson, AJ; Champoux, M; Chrousos, GP; Contoreggi, C; Gold, PW; Habib, KE; Higley, JD; Listwak, S; McCann, SM; Pushkas, J; Rice, KC; Schulkin, J; Suomi, SJ; Webster, EL; Weld, KP, 2000
)
0.31
" The dose-response profile of V(1) receptor agonist-induced neurotrophism exhibited a biphasic function, with lower concentrations inducing a significant increase while higher concentrations generally induced no significant effect."( Vasopressin-induced neurotrophism in cultured neurons of the cerebral cortex: dependency on calcium signaling and protein kinase C activity.
Brinton, RD; Chen, Q; Kim, J; Monreal, AW; Oji, G; Patel, R; Sales, A, 2000
)
0.31
" These results demonstrate that OPC-51803 is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states."( Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
Aoyama, M; Hirano, T; Kondo, K; Mori, T; Nakamura, S; Tominaga, M; Tsujimae, K; Yamamura, Y, 2000
)
0.31
" To explore relationships between CCK-B receptor activation, the HPA axis response, and AVP release, a dose-response study using the CCK-B receptor agonist pentagastrin was conducted."( Dose response of arginine vasopressin to the CCK-B agonist pentagastrin.
Abelson, JL; Bichet, DG; Le Mellédo, J, 2001
)
0.31
" At the end of the dosing period, animals were euthanized and brains were harvested."( The effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on corticotrophin-releasing hormone, arginine vasopressin, and pro-opiomelanocortin mRNA levels in the hypothalamus of the cynomolgus monkey.
Farley, A; Foster, WG; Reid, RL; Shridhar, S; Van Vugt, DA, 2001
)
0.31
" The purpose was to measure the effect of ibuprofen on urinary excretion of aquaporin-2 (u-AQP2), urinary output, urinary osmolality (u-osm) and plasma concentration of vasopressin (AVP) in a dose-response study using placebo and ibuprofen 600mg and 1200mg."( Effect of an acute oral ibuprofen intake on urinary aquaporin-2 excretion in healthy humans.
Bech, JN; Bentzen, H; Pedersen, EB; Pedersen, RS, 2001
)
0.31
" For this purpose dose-response curves (DRCs) for NA (i."( Vasopressin-induced presynaptic facilitation of sympathetic neurotransmission in the pithed rat.
Mathy, MJ; Pfaffendorf, M; Streefkerk, JO; van Zwieten, PA, 2002
)
0.31
" Analysis of dose-response curves to Ang III in forskolin-treated CTAL demonstrated that the maximal [Ca2+]i response was significantly increased without altering the EC50."( Potentiation of [Ca2+]i response to angiotensin III by cAMP in cortical thick ascending limb.
Corvol, P; Hus-Citharel, A; Llorens-Cortes, C; Marchetti, J, 2002
)
0.31
"We undertook a dose-response study to examine the impact of aging on resting NBF and its vasoreactivity to vasopressin."( The impact of aging on vasa nervorum, nerve blood flow and vasopressin responsiveness.
Kihara, M; Okuda, K; Shioyama, M; Takahashi, M, 2002
)
0.31
" Rats dosed with chlorpyrifos and saline underwent a 2-3 degrees reduction in core temperature >50% decrease in motor activity."( Possible role of vasopressin in the thermoregulatory response to chlorpyrifos in the rat.
Gordon, CJ; Yang, YL, 2002
)
0.31
" Dosage of OXC, serum levels of the active metabolite of OXC, antiepileptic comedication or patients' age and gender were of no predictive value for the development of hyponatremia."( Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children.
Boenigk, HE; Holtmann, M; Korn-Merker, E; Krause, M; Opp, J; Tokarzewski, M, 2002
)
0.31
" Dose-response curves were generated by plotting the change in the bone vascular resistance index (mmHg/bone perfusion units) evoked by each dose of agonist."( Two week nicotine treatment selectively increases bone vascular constriction in response to norepinephrine.
Feitelson, JB; Fleming, JT; Roberts, CS; Rowell, PP, 2003
)
0.32
" Rightward shift of the dose-response curves due to coinfusion of inhibitors served to assess contribution of different pathways: trimethoxybenzoate (TMB-8) against Ca2+ mobilization, nifedipine against Ca2+ influx, staurosporine and Ro-318220 against PKC, and Y-27632 and HA-1077 against ROK."( Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat.
Bauer, J; Parekh, N, 2003
)
0.32
" They shifted dose-response curves of Ang II, norepinephrine, and AVP to sevenfold and higher values."( Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat.
Bauer, J; Parekh, N, 2003
)
0.32
" AVP was infused intravenously at the clinical dosage (0."( Oxygen distribution in microcirculation after arginine vasopressin-induced arteriolar vasoconstriction.
Dünser, MW; Friesenecker, B; Hasibeder, W; Intaglietta, M; Knotzer, H; Martini, J; Mayr, AJ; Tsai, AG, 2004
)
0.32
" Dose-response curves were produced with the thromboxane-mimetics U46619 and U44069 (10(-10)-2 x 10(-6)M), arginine vasopressin (10(-10)-5 x 10(-8)M) and endothelin-1 (10(-11)-3 x 10(-7)M) in the presence or absence of 50 micromol l(-1) glibenclamide."( Glibenclamide inhibits agonist-induced vasoconstriction of placental chorionic plate arteries.
Baker, PN; Fyfe, GK; Greenwood, SL; Taggart, MJ; Wareing, M,
)
0.13
"Pre-incubation with 50 micromol l(-1) glibenclamide significantly right-shifted dose-response curves to all vasoconstrictive agonists tested (repeated measures ANOVA)."( Glibenclamide inhibits agonist-induced vasoconstriction of placental chorionic plate arteries.
Baker, PN; Fyfe, GK; Greenwood, SL; Taggart, MJ; Wareing, M,
)
0.13
"4 mg/5 microl pilocarpine intracerebroventricularly, to obtain the dose-response relationship for behavioural seizures."( Arginine vasopressin does not contribute to seizures induced by intracerebroventricularly-injected pilocarpine.
Gulec, G; Isbil-Buyukcoskun, N, 2005
)
0.33
" No differences in jejunal mucosal oxygenation occurred between study groups at any dosage during the experimental protocol."( Arginine vasopressin does not alter mucosal tissue oxygen tension and oxygen supply in an acute endotoxemic pig model.
Brandner, J; Dünser, MW; Friesenecker, B; Hasibeder, WR; Hausdorfer, H; Iannetti, C; Knotzer, H; Maier, S; Pajk, W; Torgersen, C; Ulmer, H, 2006
)
0.33
" It is known from patients with advanced vasodilatory shock that AVP exerts strong additional vasoconstriction when incremental dosage increases of NE have no further effect on mean arterial blood pressure (MAP)."( Arteriolar vasoconstrictive response: comparing the effects of arginine vasopressin and norepinephrine.
Dünser, MW; Friesenecker, BE; Hasibeder, WR; Intaglietta, M; Martini, J; Tsai, AG; Ulmer, H; Wenzel, V, 2006
)
0.33
" Response selectivity was further established in a dose-response study that revealed an inverted U-shaped function."( New insights into neuropeptide modulation of aggression: field studies of arginine vasotocin in a territorial tropical damselfish.
Bass, AH; Santangelo, N, 2006
)
0.33
" AVP pretreatment significantly increased the contractile response of SMA to NE and Ca2+ and made the cumulative dose-response curve of NE and Ca2+ shift to the left."( Effect of arginine vasopressin on vascular reactivity and calcium sensitivity after hemorrhagic shock in rats and its relationship to Rho-kinase.
Li, T; Liu, L; Xu, J; Yang, G, 2006
)
0.33
"9 times) of bCRH induced bleating, but no dosage of AVP induced bleating."( Comparison between the central effects of CRH and AVP in steers.
Ito, S; Nakamura, M; Sato, Y; Yayou, K, 2008
)
0.35
" Although any AVP-induced myocardial ischemia undoubtedly is a crucial safety issue, these findings need to be discussed in the context of the model design, the dosing of AVP as well as the complex direct, afterload-independent and systemic, vasoconstriction-related effects on the heart."( Vasopressin in vasodilatory shock: is the heart in danger?
Asfar, P; Calzia, E; Georgieff, M; Hauser, B; Laporte, R; Radermacher, P, 2008
)
0.35
" Our results do not support weight-based dosing of vasopressin, unlike the dosing for catecholamine vasopressors."( Lack of an effect of body mass on the hemodynamic response to arginine vasopressin during septic shock.
Bauer, SR; Cha, SS; Lam, SW; Oyen, LJ, 2008
)
0.35
" The latest international guidelines recommend AVP as an alternative vasopressor drug which may replace the first or second dosage of epinephrine in the treatment of pulseless arrest If the combined use of AVP and epinephrine is superior to epinephrine alone in terms of improved hospital admission and discharge rates this needs to be re-confirmed by the results of an ongoing multicenter trial."( Role of arginine vasopressin in the setting of cardiopulmonary resuscitation.
Dünser, MW; Raab, H; Wenzel, V, 2008
)
0.35
" There was a dose-response relationship between VFs and BP status."( A pilot study on level of blood vasoactive factors in prehypertensive and hypertensive patients.
Liu, J; Liu, Y; Wang, Z; Wen, J; Wen, S; Wu, Z, 2008
)
0.35
"Our previous study showed that small dosage of arginine vasopressin (AVP) had beneficial effect on shock by improving the shock-induced vascular hyporeactivity."( Role of V1a receptor in AVP-induced restoration of vascular hyporeactivity and its relationship to MLCP-MLC20 phosphorylation pathway.
Chen, W; Li, T; Liu, L; Ming, J; Xu, J; Yang, G, 2010
)
0.36
"05 microg/kg/min until maximal heart rate of 160 beats/min; n = 12) or AVP (1 to 5 ng/kg/min; supplemented by noradrenaline if the maximal AVP dosage failed to maintain mean blood pressure; n = 12) to treat sepsis-associated hypotension."( Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial.
Asfar, P; Calzia, E; Georgieff, M; Giudici, R; Gröger, M; Hauser, B; Laporte, R; Möller, P; Ploner, F; Radermacher, P; Scheuerle, A; Simon, F; Vogt, JA; Wachter, U, 2009
)
0.35
" A dose-response profile revealed a noncompetitive property of VRQ397; correspondingly, VRQ397 bound specifically to V2R-expressing cells could not displace its natural ligand, AVP, but modulated AVP binding kinetics (dissociation rate)."( VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist.
Beauregard, K; Bouvier, M; Brault, S; Chemtob, S; Duhamel, F; Gobeil, F; Guillon, G; Hamdan, FF; Hamel, D; Hardy, P; Heveker, N; Hou, X; Joyal, JS; Kaul, R; Lahaie, I; Lubell, WD; Nedev, H; Quiniou, C; Rihakova, L; Sapieha, P; Saragovi, HU; Shao, Z, 2009
)
0.35
" Neither disease severity nor L-dopa dosage correlated with plasma AVP levels."( Increased plasma arginine vasopressin levels in dopamine agonist-treated Parkinson's disease patients.
Arai, M, 2011
)
0.37
" To test the association between concomitant AVP/hydrocortisone use and mortality, a multivariate regression and Cox model (adjusted for admission year, initial AVP dosage and the Sepsis-related Organ Failure Assessment score before AVP) as well as a propensity score-based analysis were used."( Concomitant arginine-vasopressin and hydrocortisone therapy in severe septic shock: association with mortality.
Dünser, MW; Luckner, G; Rex, C; Schmittinger, CA; Schröder, DC; Torgersen, C; Ulmer, H, 2011
)
0.37
"8%) at a median daily dosage of 300 (200-300) mg."( Concomitant arginine-vasopressin and hydrocortisone therapy in severe septic shock: association with mortality.
Dünser, MW; Luckner, G; Rex, C; Schmittinger, CA; Schröder, DC; Torgersen, C; Ulmer, H, 2011
)
0.37
" In the first group of animals (n = 11) the dose-response relationship was measured."( The effect of vasopressin on choroidal blood flow, intraocular pressure, and orbital venous pressure in rabbits.
Bogner, B; Branka, M; Kiel, JW; Radner, W; Reitsamer, HA; Runge, C; Schroedl, F; Strohmaier, C; Tockner, B; Trost, A, 2011
)
0.37
" No tolvaptan accumulation was found after multiple dosing for 7 days."( Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.
Azuma, J; Hasunuma, T; Kim, SR; Kondo, M; Okada, T; Sato, O, 2011
)
0.37
" Although mean plasma AVP levels are significantly higher in treated PD patients than in treatment-naïve patients, neither disease severity nor levodopa/carbidopa dosage (range, 300/30-850/85 mg) correlates with plasma AVP levels."( Levodopa in combination with carbidopa does not affect plasma arginine vasopressin levels in treatment-naïve older patients with Parkinson's disease: A before-after study.
Arai, M, 2012
)
0.38
"There are sustained cumulative biologic actions for the massage and touch interventions that persist for several days or a week, and these differ profoundly depending on the dosage (frequency) of sessions."( A preliminary study of the effects of repeated massage on hypothalamic-pituitary-adrenal and immune function in healthy individuals: a study of mechanisms of action and dosage.
Bresee, C; Rapaport, MH; Schettler, P, 2012
)
0.38
"Fluid deprivation tests were performed without (d0) and after one (d1) and five days (d5) of oral prednisolone (Pred) pretreatment in a dosage relevant to drug therapy (30 mg/day)."( Arginine vasopressin-dependent and AVP-independent mechanisms of renal fluid absorption during thirsting despite glucocorticoid-mediated vasopressin suppression.
Bähr, V; Diederich, S; Mai, K; Pedersen, EB; Pfeiffer, AF; Spranger, J; Ufer, F, 2013
)
0.39
" Effects of escalating ropinirole dosage on plasma AVP levels were evaluated using a one-way analysis of variance for repeated measures, an a priori Dunnett multiple comparison test, and a regression analysis."( Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Arai, M, 2012
)
0.38
" There was no statistically significant dose-response relationship between the ropinirole dosage and plasma AVP levels."( Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Arai, M, 2012
)
0.38
"A minimal therapeutic dosage of ropinirole did not affect plasma AVP levels in patients with PD taking levodopa."( Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Arai, M, 2012
)
0.38
" Mean volumes of hypotonic fluids administered and cumulative diuretic dosing during the first 72 hours post-surgery were also not statistically different between groups."( Hyponatremia during arginine vasopressin therapy in children following cardiac surgery.
Barrett, R; Davalos, MC; Delius, RE; Mastropietro, CW; Seshadri, S; Walters, HL; Zidan, M, 2013
)
0.39
" Treatment with paroxetine was performed per os with a dosage of 20 mg/g BW."( Chronic social stress during adolescence: interplay of paroxetine treatment and ageing.
Liebl, C; Müller, MB; Scharf, SH; Schmidt, MV; Sterlemann, V, 2013
)
0.39
" Dose-response studies on isolated collecting ducts (CDs) showed an increased accumulation of cAMP in response to AVP in CHF rats compared with controls."( Congestive heart failure in rats is associated with increased collecting duct vasopressin sensitivity and vasopressin type 2 receptor reexternalization.
Brønd, L; Christensen, S; Graebe, M; Hadrup, N; Jonassen, TE; Müllertz, KM; Nielsen, J; Nielsen, S; Torp, M, 2013
)
0.39
" On multivariable regression, greater number of corticosteroid doses but not cumulative corticosteroid dosage was significantly associated with low 48-hour AVP concentration (β=-4."( Effect of corticosteroids on arginine vasopressin after pediatric cardiac surgery.
Chen, H; Mastropietro, CW; Miletic, K; Rossi, NF, 2014
)
0.4
" Les chats dans les autres groupes reçurent de la xylazine par voie intramusculaire à un dosage de 2 mg/kg de poids corporel (PC), et de la saline (comme témoin); 160 μg/kg PC de prazosin; ou 40, 160, ou 480 μg/kg PC d’atipamezole ou de yohimbine par voie intraveineuse 0,5 h plus tard."( Antagonistic effects of atipamezole, yohimbine, and prazosin on xylazine-induced diuresis in clinically normal cats.
Hikasa, Y; Miki, Y; Murahata, Y, 2014
)
0.4
" The effective dosage of common antishock agents including norepinephrine, dopamine, and AVP in healthy rats was wider than that in these diseased rats."( DIVERSITY OF VASCULAR REACTIVITY AND THE TREATMENT RESPONSE IN DIABETIC, HYPERTENSIVE, HYPERLIPIDEMIC, AND HEALTHY RATS SUBJECTED TO HEMORRHAGIC SHOCK.
Chen, XY; Li, T; Liu, LM; Wu, Y; Zhu, Y, 2016
)
0.43
" Studies with more subjects are warranted to define optimal dosing strategies of these medications in an acute pulmonary hypertensive crisis."( Hemodynamic Effects of Phenylephrine, Vasopressin, and Epinephrine in Children With Pulmonary Hypertension: A Pilot Study.
Feinstein, JA; Ogawa, MT; Peng, LF; Ramamoorthy, C; Siehr, SL; Yang, W, 2016
)
0.43
"Reliable data at population level are essential to firmly establish links between fluid intake, hydration and health, investigate dose-response relationships and develop meaningful public health strategies or reference intake values."( Relevance of Assessment Methods for Fluid Intake.
Bardosono, S; Gandy, J; Guelinckx, I; Kavouras, SA; Martinez, H; Moreno, LA; Salas-Salvadó, J, 2016
)
0.43
" The control group received the oral administration of distilled water (4 ml/kg), and the experimental animals were subdivided into two groups consisting of 10 animals each by the dosage of isosorbide (1."( Isosorbide-Induced Decompression Effect on the Scala Media: Participation of Plasma Osmolality and Plasma Arginine Vasopressin.
Furukawa, T; Kakigi, A; Nibu, KI; Takeda, S; Takeda, T; Uehara, N; Yanagisawa, S, 2017
)
0.46
" Its basal dosage may identify nephrogenic DI whereas osmotic stimulated dosage would discriminate central DI and primary polydipsia."(
Borson-Chazot, F; Lasolle, H, 2016
)
0.43
" Although sleep deprivation (SD) is widely considered as an independent risk factor for cognition retardations, however, little is well understood about the synergistic role of caffeine dosage and SD for cognitive performance."( Caffeine-related effects on cognitive performance: Roles of apoptosis in rat hippocampus following sleep deprivation.
Huang, P; Huang, X; Li, H; Wang, P; Xie, G, 2021
)
0.62
" Acute disease management focuses on fixed dosing of antidiuretic hormone analogues and calculated prescriptions of obligate daily water intake."( Adipsic diabetes insipidus.
Cardona, Z; Eisenberg, Y; Kothari, V, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
cardiovascular drugA drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume.
hematologic agentDrug that acts on blood and blood-forming organs and those that affect the hemostatic system.
mitogenA chemical substance that encourages a cell to commence cell division, triggering mitosis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
vasopressinA family of cyclic nonapeptide hormones found in most mammals. Synthesised in the hypothalamus and stored in the post-pituitary, vasopressins play a key role in homeostasis, particularly in regulating the body's water content. Together with the similar neuropeptide oxytocin, they are believed to influence social cognition and behaviour.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Vascular smooth muscle contraction013

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.06420.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Vasopressin V2 receptorHomo sapiens (human)IC50 (µMol)0.24200.00001.12137.0000AID734445
Vasopressin V2 receptorHomo sapiens (human)Ki0.00900.00040.43453.9811AID1494504; AID593570; AID703461; AID703466
Oxytocin receptorHomo sapiens (human)Ki0.00470.00010.07180.9780AID1494505; AID1593563; AID549468; AID593571; AID703451
Vasopressin V1a receptorHomo sapiens (human)Ki0.00130.00020.62357.0300AID1494502; AID298221; AID298222; AID298223; AID298224; AID298225; AID298228; AID298229; AID298230; AID593568; AID703456
Vasopressin V1b receptorHomo sapiens (human)Ki0.00110.00050.18971.7820AID1494503; AID593569; AID703454
Vasopressin V1b receptorRattus norvegicus (Norway rat)Ki0.00030.00030.01580.0610AID277898
Translocator proteinMus musculus (house mouse)Ki0.00040.00030.00030.0004AID277899
Oxytocin receptorRattus norvegicus (Norway rat)Ki0.00120.00090.04890.2300AID277901
Vasopressin V2 receptor Rattus norvegicus (Norway rat)Ki0.00040.00030.97919.7000AID277899
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Translocator proteinRattus norvegicus (Norway rat)EC50 (µMol)0.00010.00000.00350.0156AID613481
Vasopressin V2 receptorHomo sapiens (human)EC50 (µMol)0.00010.00000.55066.7000AID1178647; AID260559; AID613481
Oxytocin receptorHomo sapiens (human)EC50 (µMol)0.01690.00000.08050.8810AID1178646; AID1593562; AID549467; AID593577; AID613482
Vasopressin V1a receptorRattus norvegicus (Norway rat)EC50 (µMol)0.00010.00010.26541.0000AID613485
Vasopressin V1a receptorRattus norvegicus (Norway rat)Kd0.00060.00060.00060.0007AID213776; AID213779; AID217056; AID217716
Vasopressin V1a receptorHomo sapiens (human)EC50 (µMol)0.00020.00000.19713.2000AID1178648; AID1593564; AID613479
Vasopressin V1b receptorHomo sapiens (human)EC50 (µMol)0.00300.00000.03600.2400AID1178649; AID1593565; AID593575; AID613480
Vasopressin V2 receptorBos taurus (cattle)Kd0.00150.00150.00150.0015AID217844
Vasopressin V1b receptorRattus norvegicus (Norway rat)Kd0.00070.00070.00070.0007AID217056; AID217716
Vasopressin V2 receptor Rattus norvegicus (Norway rat)Kd0.00150.00150.00150.0015AID217687
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vasopressin V2 receptorHomo sapiens (human)Kact0.00030.00030.00640.0095AID703460
Vasopressin V1b receptorRattus norvegicus (Norway rat)Kact0.00230.00230.00230.0023AID277907
Translocator proteinMus musculus (house mouse)Kact0.00230.00230.00230.0023AID277907
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (109)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
positive regulation of systemic arterial blood pressureVasopressin V2 receptorHomo sapiens (human)
renal water retentionVasopressin V2 receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
activation of adenylate cyclase activityVasopressin V2 receptorHomo sapiens (human)
hemostasisVasopressin V2 receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
negative regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
positive regulation of gene expressionVasopressin V2 receptorHomo sapiens (human)
telencephalon developmentVasopressin V2 receptorHomo sapiens (human)
response to cytokineVasopressin V2 receptorHomo sapiens (human)
positive regulation of intracellular signal transductionVasopressin V2 receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V2 receptorHomo sapiens (human)
suckling behaviorOxytocin receptorHomo sapiens (human)
response to amphetamineOxytocin receptorHomo sapiens (human)
muscle contractionOxytocin receptorHomo sapiens (human)
cell surface receptor signaling pathwayOxytocin receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationOxytocin receptorHomo sapiens (human)
heart developmentOxytocin receptorHomo sapiens (human)
lactationOxytocin receptorHomo sapiens (human)
memoryOxytocin receptorHomo sapiens (human)
response to xenobiotic stimulusOxytocin receptorHomo sapiens (human)
positive regulation of norepinephrine secretionOxytocin receptorHomo sapiens (human)
telencephalon developmentOxytocin receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicOxytocin receptorHomo sapiens (human)
response to estradiolOxytocin receptorHomo sapiens (human)
response to progesteroneOxytocin receptorHomo sapiens (human)
response to anoxiaOxytocin receptorHomo sapiens (human)
response to cytokineOxytocin receptorHomo sapiens (human)
social behaviorOxytocin receptorHomo sapiens (human)
response to cocaineOxytocin receptorHomo sapiens (human)
maternal behaviorOxytocin receptorHomo sapiens (human)
sperm ejaculationOxytocin receptorHomo sapiens (human)
eating behaviorOxytocin receptorHomo sapiens (human)
response to peptide hormoneOxytocin receptorHomo sapiens (human)
estrous cycleOxytocin receptorHomo sapiens (human)
positive regulation of blood pressureOxytocin receptorHomo sapiens (human)
digestive tract developmentOxytocin receptorHomo sapiens (human)
positive regulation of synapse assemblyOxytocin receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicOxytocin receptorHomo sapiens (human)
positive regulation of penile erectionOxytocin receptorHomo sapiens (human)
ERK1 and ERK2 cascadeOxytocin receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionOxytocin receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisOxytocin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayOxytocin receptorHomo sapiens (human)
female pregnancyOxytocin receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinOxytocin receptorHomo sapiens (human)
positive regulation of vasoconstrictionOxytocin receptorHomo sapiens (human)
maternal process involved in parturitionOxytocin receptorHomo sapiens (human)
cellular response to hormone stimulusOxytocin receptorHomo sapiens (human)
maternal aggressive behaviorVasopressin V1a receptorHomo sapiens (human)
positive regulation of systemic arterial blood pressureVasopressin V1a receptorHomo sapiens (human)
generation of precursor metabolites and energyVasopressin V1a receptorHomo sapiens (human)
activation of phospholipase C activityVasopressin V1a receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVasopressin V1a receptorHomo sapiens (human)
negative regulation of female receptivityVasopressin V1a receptorHomo sapiens (human)
grooming behaviorVasopressin V1a receptorHomo sapiens (human)
blood circulationVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V1a receptorHomo sapiens (human)
positive regulation of heart rateVasopressin V1a receptorHomo sapiens (human)
positive regulation of glutamate secretionVasopressin V1a receptorHomo sapiens (human)
myotube differentiationVasopressin V1a receptorHomo sapiens (human)
calcium-mediated signalingVasopressin V1a receptorHomo sapiens (human)
telencephalon developmentVasopressin V1a receptorHomo sapiens (human)
positive regulation of cell growthVasopressin V1a receptorHomo sapiens (human)
positive regulation of prostaglandin biosynthetic processVasopressin V1a receptorHomo sapiens (human)
positive regulation of cellular pH reductionVasopressin V1a receptorHomo sapiens (human)
social behaviorVasopressin V1a receptorHomo sapiens (human)
cellular response to water deprivationVasopressin V1a receptorHomo sapiens (human)
maternal behaviorVasopressin V1a receptorHomo sapiens (human)
sperm ejaculationVasopressin V1a receptorHomo sapiens (human)
response to corticosteroneVasopressin V1a receptorHomo sapiens (human)
negative regulation of transmission of nerve impulseVasopressin V1a receptorHomo sapiens (human)
transport across blood-brain barrierVasopressin V1a receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V1a receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V1a receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V1a receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V1a receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V1b receptorHomo sapiens (human)
activation of phospholipase C activityVasopressin V1b receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVasopressin V1b receptorHomo sapiens (human)
positive regulation of phospholipase A2 activityVasopressin V1b receptorHomo sapiens (human)
regulation of cell population proliferationVasopressin V1b receptorHomo sapiens (human)
positive regulation of MAPK cascadeVasopressin V1b receptorHomo sapiens (human)
symbiont entry into host cellVasopressin V1b receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processVasopressin V1b receptorHomo sapiens (human)
positive regulation of arachidonic acid secretionVasopressin V1b receptorHomo sapiens (human)
transport across blood-brain barrierVasopressin V1b receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V1b receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V1b receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V1b receptorHomo sapiens (human)
positive regulation of gene expressionVasopressin V2 receptorBos taurus (cattle)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
vasopressin receptor activityVasopressin V2 receptorHomo sapiens (human)
protein bindingVasopressin V2 receptorHomo sapiens (human)
peptide bindingVasopressin V2 receptorHomo sapiens (human)
peptide hormone bindingOxytocin receptorHomo sapiens (human)
peptide bindingOxytocin receptorHomo sapiens (human)
vasopressin receptor activityOxytocin receptorHomo sapiens (human)
oxytocin receptor activityOxytocin receptorHomo sapiens (human)
vasopressin receptor activityVasopressin V1a receptorHomo sapiens (human)
protein kinase C bindingVasopressin V1a receptorHomo sapiens (human)
protein bindingVasopressin V1a receptorHomo sapiens (human)
peptide hormone bindingVasopressin V1a receptorHomo sapiens (human)
V1A vasopressin receptor bindingVasopressin V1a receptorHomo sapiens (human)
peptide bindingVasopressin V1a receptorHomo sapiens (human)
vasopressin receptor activityVasopressin V1b receptorHomo sapiens (human)
protein kinase C bindingVasopressin V1b receptorHomo sapiens (human)
peptide bindingVasopressin V1b receptorHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endosomeVasopressin V2 receptorHomo sapiens (human)
endoplasmic reticulumVasopressin V2 receptorHomo sapiens (human)
Golgi apparatusVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
membraneVasopressin V2 receptorHomo sapiens (human)
endocytic vesicleVasopressin V2 receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneVasopressin V2 receptorHomo sapiens (human)
perinuclear region of cytoplasmVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
plasma membraneOxytocin receptorHomo sapiens (human)
microvillusOxytocin receptorHomo sapiens (human)
adherens junctionOxytocin receptorHomo sapiens (human)
apical plasma membraneOxytocin receptorHomo sapiens (human)
plasma membraneOxytocin receptorHomo sapiens (human)
endosomeVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
endocytic vesicleVasopressin V1a receptorHomo sapiens (human)
plasma membraneVasopressin V1a receptorHomo sapiens (human)
endosomeVasopressin V1b receptorHomo sapiens (human)
Golgi apparatusVasopressin V1b receptorHomo sapiens (human)
plasma membraneVasopressin V1b receptorHomo sapiens (human)
plasma membraneVasopressin V1b receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorBos taurus (cattle)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (209)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1150132Oxytocic activity in rat uterus in absence of Mg2+1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.
AID1593564Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID217844Inhibition of radioligand [3H]AVP binding to V2 receptor in bovine kidney inner medulla membrane1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7.
AID593574Selectivity ratio of Ki for human oxytocin receptor to Ki for human vasopressin V1b receptor2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID1178653Antagonist activity at human vasopressin V1a expressed in AVP-stimulated HEK293 cells after 5 hrs by firefly luciferase reporter gene assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
New, potent, and selective peptidic oxytocin receptor agonists.
AID277902Selectivity index, Ki for rat V1b receptor/Ki for rat V2 receptor2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID1178649Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
New, potent, and selective peptidic oxytocin receptor agonists.
AID1178652Selectivity ratio of EC50 for human vasopressin V1b expressed in HEK293 cells to EC50 for human oxytocin receptor expressed in CHO-K1 cells2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
New, potent, and selective peptidic oxytocin receptor agonists.
AID1178647Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
New, potent, and selective peptidic oxytocin receptor agonists.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID217687Compound was evaluated for its dissociation constant (Kd) to rat kidney Vasopressin V2 receptor1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Synthesis of oxytocin antagonists containing conformationally constrained amino acids in position 2.
AID277898Displacement of [3H]AVP from rat vasopressin V1b receptor expressed in At-T20 cells2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID151940Compound was evaluated for the oxytocic activity with out Mg2+.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
AID426919Volume of distribution in Wistar rat2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists.
AID613483Selectivity ratio of EC50 for human vasopressin V1b receptor to EC50 for human vasopressin V1a receptor2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
New, potent, selective, and short-acting peptidic V1a receptor agonists.
AID168769Antidiuretic test on conscious rats was determined1999Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13
Solid phase synthesis and biological activities of [Arg8]-vasopressin methylenedithioether.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1593566Selectivity ratio of EC50 for recombinant human V1a receptor expressed in HEK293 cells to EC50 for recombinant human OTR expressed in HEK293 cells2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1882821Stability of the compound in simulated gastric fluid at pH 1.2 assessed as half life measured up to 24 hrs by RP-HPLC-UV analysis2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
On the Utility of Chemical Strategies to Improve Peptide Gut Stability.
AID298224Inhibition of human vasopressin V1a receptor expressed in COS7 cells by HTRF-FRET assay using 96-well plate membranes2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID188011Compound was tested for the vasopressor activity against phenoxybenzamine treated rats, after intravenous injection.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Arginine-vasopressin analogues with high antidiuretic/vasopressor selectivity. Synthesis, biological activity, and receptor binding affinity of arginine-vasopressin analogues with substitutions in positions 1, 2, 4, 7, and 8.
AID277903Selectivity index, Ki for rat V1b receptor/Ki for rat V1a receptor2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID277899Displacement of [3H]AVP from vasopressin V2 receptor in rat kidney membranes2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID734447Stability of the compound in presence of pronase (unknown origin) assessed as degradation measured after 360 mins by HPLC analysis2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID734451Stability of the compound in presence of alpha-chymotrypsin (unknown origin) assessed as degradation measured after 120 mins by HPLC analysis2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID298229Inhibition of human vasopressin V1a receptor expressed in COS7 cells by fluorescent binding assay using 96-well plate membranes2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID426922Antidiuretic activity in fasted and hydrated Wistar rat assessed as compound potency to yield antidiuresis time of 60 mins required for urinary excretion of half the water load at 0.001 to 100 nmol/kg, sc administered immediately after water loading by mo2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists.
AID1131305Antidiuretic activity in iv dosed water loaded rat1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID1494506Selectivity index, ratio of Ki for human liver vasopressin V1a receptor to Ki for human mammary gland oxytocin receptor2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID298227Agonist activity at human oxytocin receptor expressed in CHO cells assessed as accumulation of inositol phosphate up to 1 uM2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID1131303Oxytocic activity in isolated rat uterus strips in presence of Mg2+1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID1130468Induction in uterus contraction in rat after single intravenous bolus injection1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Synthesis and biological activities of arginine-vasopressin analogues designed from a conformation-activity approach.
AID191517Uterine activity was meseared in isolated rat uterus in solutions in the absence No Mg2+ 0.5 mM in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and biological activities of arginine-vasopressin analogues with 4-hydroxyproline in position 7.
AID734454Stability of the compound in presence of pepsin (unknown origin) assessed as degradation measured after 120 mins by HPLC analysis2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID1494505Displacement of [3H]OT from human mammary gland oxytocin receptor expressed in HEK293 cell membrane after 1 hr by scintillation counting method2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID210932Toad bladder hydroosmotic activity was determined1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
[1-Desamino, 7-lysine, 8-arginine]vasotocin: attachment of reporter groups and affinity ligands through the lysine side chain.
AID1178651Selectivity ratio of EC50 for human vasopressin V1a expressed in HEK293 cells to EC50 for human oxytocin receptor expressed in CHO-K1 cells2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
New, potent, and selective peptidic oxytocin receptor agonists.
AID298230Inhibition of human vasopressin V1a receptor expressed in COS7 cells by fluorescent binding assay using 384-well plate membranes2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID678887TP_TRANSPORTER: uptake in membrane vesicles from Bsep-expressing Sf9 cells2000Molecular pharmacology, Mar, Volume: 57, Issue:3
Transport function and hepatocellular localization of mrp6 in rat liver.
AID190220In vivo antidiuretic activity in female Sprague-Dawley rats by intraperitoneal administration using Vasopressin house standard (561 IU/mg)2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Conformations and receptor activity of desmopressin analogues, which contain gamma-turn mimetics or a psi[CH(2)O] isostere.
AID1150140Antidiuretic activity in sc dosed Brattleboro rat assessed as spontaneous urine output measured every 1 hr for 24 hrs1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.
AID15828Compound was tested for antidiuretic activity in rats1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
N-Acetyl-[2-(O-methyl)tyrosine]arginine-vasopressin, an interesting antagonist of the vasopressor response to vasopressin.
AID613480Agonist activity at recombinant human vasopressin V1b receptor expressed in Flp-In-293 cells by luciferase reporter gene assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
New, potent, selective, and short-acting peptidic V1a receptor agonists.
AID188010Compound was tested for the antidiuretic activity against hydrated anaesthetized rats, after intravenous injection.1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Arginine-vasopressin analogues with high antidiuretic/vasopressor selectivity. Synthesis, biological activity, and receptor binding affinity of arginine-vasopressin analogues with substitutions in positions 1, 2, 4, 7, and 8.
AID171775Uterotonic activity in vitro in isolated rat uterus in absence of magnesium1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID298226Agonist activity at human vasopressin V1a receptor expressed in CHO cells assessed as accumulation of inositol phosphate up to 1 uM2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID613487Vasoconstriction in Wistar rat assessed as assessed as decay in vasopressive duration of action at 0.1 nmol/kg, iv bolus measured over 10 sec interval2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
New, potent, selective, and short-acting peptidic V1a receptor agonists.
AID1130464Antidiuretic effect in Brattleboro rat assessed as maximal depressions of urine flow after single intravenous bolus injection1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Synthesis and biological activities of arginine-vasopressin analogues designed from a conformation-activity approach.
AID1178656Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette mode as bolus dose2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
New, potent, and selective peptidic oxytocin receptor agonists.
AID1150188Antidiuretic activity in Brattleboro rat hereditary hypothalamic diabetes insipidus model at 100 ug/kg, sc measured over 1.7 hrs1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-deaminopenicillamine,4-valine]-8-D-arginine-vasopressin, a highly potent inhibitor of the vasopressor response to arginine-vasopressin.
AID1178650Selectivity ratio of EC50 for human vasopressin V2 expressed in HEK293 cells to EC50 for human oxytocin receptor expressed in CHO-K1 cells2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
New, potent, and selective peptidic oxytocin receptor agonists.
AID1150895Antidiuretic activity in rat1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.
AID277895Antidiuretic activity in rat2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID734448Stability of the compound in presence of pronase (unknown origin) assessed as degradation measured after 120 mins by HPLC analysis2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID1593563Displacement of [3H]OT from recombinant human OTR expressed in HEK293 cell membranes measured after 1 hr2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1148688Antidiuretic activity in iv dosed rat1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Design of potent antagonists of the vasopressor response to arginine-vasopressin.
AID1130469Reduction in vasomotor depression in chicken after single intravenous bolus injection1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Synthesis and biological activities of arginine-vasopressin analogues designed from a conformation-activity approach.
AID298221Inhibition of human vasopressin V1a receptor expressed in CHO cells by polarisation binding assay using 96-well plate membranes2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID613482Agonist activity at human OT receptor expressed in CHO-K1 cells by luciferase reporter gene assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
New, potent, selective, and short-acting peptidic V1a receptor agonists.
AID1882822Stability of the compound in simulated intestinal fluid at pH 6.8 assessed as half life measured up to 24 hrs by RP-HPLC-UV analysis2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
On the Utility of Chemical Strategies to Improve Peptide Gut Stability.
AID1494504Displacement of [3H]AVP from human kidney vasopressin V2 receptor expressed in HEK293 cell membrane after 1 hr by scintillation counting method2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID426914Agonist activity at oxytocin receptor in Wistar rat uterus assessed as uterotonic activity in absence of Mg2+2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists.
AID260559Binding to human V2 receptor expressed in LV2 cells by cAMP production2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.
AID298225Inhibition of human vasopressin V1a receptor expressed in COS7 cells by HTRF-FRET assay using 384-well plate membranes2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID593570Displacement of [3H]AVP from human vasopressin V2 receptor expressed CHO cells after 60 mins2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID613481Agonist activity at recombinant human vasopressin V2 receptor expressed in HEK293 cells by luciferase reporter gene assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
New, potent, selective, and short-acting peptidic V1a receptor agonists.
AID277897Activity at OT receptor assessed as oxytocic activity in absence of magnesium2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID230905Ratio of antidiuretic potency vs vasopressor potency1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Arginine-vasopressin analogues with high antidiuretic/vasopressor selectivity. Synthesis, biological activity, and receptor binding affinity of arginine-vasopressin analogues with substitutions in positions 1, 2, 4, 7, and 8.
AID1150141Ratio of antidiuretic activity in Brattleboro rat to vasopressor activity in rat1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.
AID1131306Vasopressor activity in phenoxybenzamine-treated rat1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID549467Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Modulating oxytocin activity and plasma stability by disulfide bond engineering.
AID593568Displacement of [3H]AVP from human vasopressin V1a receptor expressed CHO cells after 60 mins2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID277901Displacement of [3H]AVP from rat OT receptor expressed in CHO cells2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID1150896Vasopressor activity in rat1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.
AID250210Compound was evaluated for antidiuretic activity with t1/2 of 60 in male rats by modified Burn test2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin.
AID213779Negative log of Kd.1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Preparation and biological activities of potential vasopressin photoaffinity labels.
AID217716Inhibition of radioligand [3H]AVP binding to V1 receptor in rat liver plasma membrane1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7.
AID613485Agonist activity at recombinant rat vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
New, potent, selective, and short-acting peptidic V1a receptor agonists.
AID1494503Displacement of [3H]AVP from human vasopressin V1b receptor expressed in HEK293 cell membrane after 1 hr by scintillation counting method2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID613484Selectivity ratio of EC50 for human oxytocin receptor to EC50 for human vasopressin V1a receptor2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
New, potent, selective, and short-acting peptidic V1a receptor agonists.
AID171776Uterotonic activity in vitro in isolated rat uterus in presence of magnesium1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID188190Pressor activity on urethane-anesthetized, phenoxybenzamine-treated rat.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and biological activities of arginine-vasopressin analogues with 4-hydroxyproline in position 7.
AID172982Antidiuretic activity on water loaded, ethanol-anesthetized rat.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and biological activities of arginine-vasopressin analogues with 4-hydroxyproline in position 7.
AID593569Displacement of [3H]AVP from human vasopressin V1b receptor expressed CHO cells after 60 mins2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID1130472Reduction in fractional excretion of sodium in Sprague-Dawley rat at 4.2 x 10'-11 mol, single intravenous bolus injection1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Synthesis and biological activities of arginine-vasopressin analogues designed from a conformation-activity approach.
AID277905Activity at vasopressin V2 receptor in rat kidney membranes assessed as adenylate cyclase activity2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID426923Antidiuretic activity in fasted and hydrated Wistar rat assessed as compound potency to yield antidiuresis time of 200 mins required for urinary excretion of half the water load at 0.001 to 100 nmol/kg, sc administered immediately after water loading by m2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists.
AID426921Antidiuretic activity in fasted and hydrated Wistar rat assessed as compound required to yield antidiuresis time of 200 mins required for urinary excretion of half the water load at 0.001 to 100 nmol/kg, sc administered immediately after water loading by 2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists.
AID1130474Increase in urine osmolality in Sprague-Dawley rat measured per liter at 4.2 x 10'-11 mol, single intravenous bolus injection (Rvb = 200 mosm)1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Synthesis and biological activities of arginine-vasopressin analogues designed from a conformation-activity approach.
AID213778Relative affinity of compound expressed in percent compared to vasopressin1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Preparation and biological activities of potential vasopressin photoaffinity labels.
AID593575Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID1130470Reduction in urine flow in Sprague-Dawley rat at 4.2 x 10'-11 mol, single intravenous bolus injection1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Synthesis and biological activities of arginine-vasopressin analogues designed from a conformation-activity approach.
AID1593568Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method relative to oxytocin2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID277900Displacement of [3H]AVP from vasopressin V1a receptor in rat liver membrane2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID1593562Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID703454Displacement of [3H]-AVP from human vasopressin V1b receptor expressed in CHO cells after 30 mins2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
AID1150894Activity at oxytocin receptor in rat uterus in presence of Mg2+1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.
AID169037In vitro biological activity in the absence of magnesium ions was determined in rats by Uterotonic test1999Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13
Solid phase synthesis and biological activities of [Arg8]-vasopressin methylenedithioether.
AID217056Compound was evaluated for its dissociation constant (Kd) to rat liver Vasopressin V1 receptor1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Synthesis of oxytocin antagonists containing conformationally constrained amino acids in position 2.
AID703466Displacement of [3H]-AVP from human vasopressin V2 receptor expressed in CHO cells after 30 mins2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
AID613479Agonist activity at recombinant human vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
New, potent, selective, and short-acting peptidic V1a receptor agonists.
AID593578Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay relative to oxytocin2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID703451Displacement of [3H]-AVP from human oxytocin receptor expressed in CHO cells after 30 mins2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
AID1150133Oxytocic activity in rat uterus in presence of Mg2+1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.
AID549466Half life in human serum by LC/MS and RP-HPLC method2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Modulating oxytocin activity and plasma stability by disulfide bond engineering.
AID171590The compound was tested for milk ejection activity in rat1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID172984Compound was tested for antidiuretic activity in rats under ethanol anesthesia1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
AID734449Stability of the compound in presence of pronase (unknown origin) assessed as degradation measured after 60 mins by HPLC analysis2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID217544Antidiuretic activity at V2 receptor.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
AID62809Antagonist activity was measured by maximum urine osmolality with a dose of 100 ug/kg peptide after pretreatment with indomethacin (3 ng/kg) in dog1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Dicarbavasopressin antagonist analogues exhibit reduced in vivo agonist activity.
AID734455Stability of the compound in presence of pepsin (unknown origin) assessed as degradation measured after 60 mins by HPLC analysis2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID1130467Induction in blood pressure in rat after single intravenous bolus injection1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Synthesis and biological activities of arginine-vasopressin analogues designed from a conformation-activity approach.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID703461Displacement of [3H]-AVP from human vasopressin V2 receptor expressed in CHO cells after 30 mins by saturation binding assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
AID593577Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID593573Selectivity ratio of Ki for human vasopressin V2 receptor to Ki for human vasopressin V1b receptor2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID1178646Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
New, potent, and selective peptidic oxytocin receptor agonists.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID277904Selectivity index, Ki for rat V1b receptor/Ki for rat OT receptor2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID734450Stability of the compound in presence of alpha-chymotrypsin (unknown origin) assessed as degradation measured after 360 mins by HPLC analysis2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID250376Compound was evaluated for in vitro uterotonic activity in the absence of magnesium ions in female wistar rats2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin.
AID151938Compound was evaluated for the oxytocic activity with 0.5 mM Mg2+.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
AID1148686Vasopressor activity in iv dosed phenoxybenzamine treated rat1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Design of potent antagonists of the vasopressor response to arginine-vasopressin.
AID593572Selectivity ratio of Ki for human vasopressin V1a receptor to Ki for human vasopressin V1b receptor2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID1130465Induction in blood pressure in rat at 4.2 x 10'-11 mol, single intravenous bolus injection1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Synthesis and biological activities of arginine-vasopressin analogues designed from a conformation-activity approach.
AID298228Inhibition of human vasopressin V1a receptor expressed in COS7 cells by fluorescent binding assay using 96-well plate cells2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID230130Tested for the ratio of antidiuretic potency to uterotonic potency(A/O)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID426920Antidiuretic activity in fasted and hydrated Wistar rat assessed as compound required to yield antidiuresis time of 60 mins required for urinary excretion of half the water load at 0.001 to 100 nmol/kg, sc administered immediately after water loading by m2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists.
AID613478Selectivity ratio of EC50 for human vasopressin V2 receptor to EC50 for human vasopressin V1a receptor2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
New, potent, selective, and short-acting peptidic V1a receptor agonists.
AID1494507Selectivity index, ratio of Ki for human mammary gland oxytocin receptor to Ki for human liver vasopressin V1a receptor2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID171948Vasopressor test using phonoxybenzamine treated male rats was determined1999Bioorganic & medicinal chemistry letters, Jul-05, Volume: 9, Issue:13
Solid phase synthesis and biological activities of [Arg8]-vasopressin methylenedithioether.
AID703460Agonist activity at human vasopressin V2 receptor expressed in CHO cells assessed as cAMP accumulation after 30 mins by TR-FRET based HTRF assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
AID734452Stability of the compound in presence of alpha-chymotrypsin (unknown origin) assessed as degradation measured after 60 mins by HPLC analysis2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID277907Activity at rat vasopressin V1b receptor expressed in At-T20 cells assessed as phospholipase C activation2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID734453Stability of the compound in presence of pepsin (unknown origin) assessed as degradation measured after 360 mins by HPLC analysis2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID593571Displacement of [3H]AVP from human oxytocin receptor expressed CHO cells after 60 mins2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.
AID1131304Vasodepressor activity in chicken1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
[3-(1,4-Cyclohexadienyl)-L-alanine,8-lysine]vasopressin: synthesis and some pharmacological properties.
AID176059Antivasopressor activity in phenoxybenzamine treated rats under urethane anesthesia was determined; Agonistic activity was observed1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
AID734445Binding affinity to vasopression V2 receptor (unknown origin) on isolated cell membrane by vasopression-self competition binding assay2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
A comparative protease stability study of synthetic macrocyclic peptides that mimic two endocrine hormones.
AID277896Vasopressor activity in rat2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID1593567Selectivity ratio of EC50 for recombinant human V1b receptor expressed in HEK293 cells to EC50 for recombinant human OTR expressed in HEK293 cells2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID217245Vasopressor activity at V1a receptor1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
AID250059Compound was evaluated for vasopressor activity in phenoxybenzamine-treated male rats2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin.
AID213776Binding potency against V1 receptor in rat liver cells1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Preparation and biological activities of potential vasopressin photoaffinity labels.
AID1150893Activity at oxytocin receptor in rat uterus1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.
AID298223Inhibition of human vasopressin V1a receptor expressed in COS7 cells by HTRF-FRET assay using 96-well plate cells2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID1130477Decrease in glomerular filtration rate in Sprague-Dawley rat at 4.2 x 10'-11 mol, single intravenous bolus injection1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
Synthesis and biological activities of arginine-vasopressin analogues designed from a conformation-activity approach.
AID703456Displacement of [3H]-AVP from human vasopressin V1a receptor expressed in CHO cells after 30 mins2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
AID298222Inhibition of human vasopressin V1a receptor expressed in CHO cells by polarisation binding assay using 384-well plate membranes2007Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
AID1150897Ratio of antidiuretic activity in rat to vasopressor activity in rat1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.
AID1494502Displacement of [3H]AVP from human liver vasopressin V1a receptor expressed in HEK293 cell membrane after 1 hr by scintillation counting method2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.
AID230132Tested for the ratio of antidiuretic potency to uterotonic potency(A/P)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID549468Displacement of [3H]OT from oxytocin receptor expressed in COS1 cells2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Modulating oxytocin activity and plasma stability by disulfide bond engineering.
AID1178648Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
New, potent, and selective peptidic oxytocin receptor agonists.
AID426916Agonist activity at vasopressin V1a receptor in phenoxybenzamine-treated Wistar rat uterus assessed as arterial vasopressor activity2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists.
AID63427Antagonist activity was measured by maximum urine flow with a dose of 100 ug/kg peptide1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Dicarbavasopressin antagonist analogues exhibit reduced in vivo agonist activity.
AID1593565Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.
AID1150135Vasopressor activity in rat1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1997Endocrinology, Oct, Volume: 138, Issue:10
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2000British journal of pharmacology, Apr, Volume: 129, Issue:8
Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)2005British journal of pharmacology, Nov, Volume: 146, Issue:5
Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1998The Journal of pharmacology and experimental therapeutics, Dec, Volume: 287, Issue:3
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2002Endocrinology, Dec, Volume: 143, Issue:12
[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)1996FEBS letters, Nov-18, Volume: 397, Issue:2-3
Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)2002Endocrinology, Dec, Volume: 143, Issue:12
[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1998The Journal of pharmacology and experimental therapeutics, Dec, Volume: 287, Issue:3
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)1995Life sciences, , Volume: 57, Issue:24
Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)1999British journal of obstetrics and gynaecology, Oct, Volume: 106, Issue:10
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)2000European journal of biochemistry, Jul, Volume: 267, Issue:13
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2000Kidney international, Oct, Volume: 58, Issue:4
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1999British journal of obstetrics and gynaecology, Oct, Volume: 106, Issue:10
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1997Biochemical pharmacology, Jun-01, Volume: 53, Issue:11
1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)1995The EMBO journal, May-15, Volume: 14, Issue:10
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)1999British journal of obstetrics and gynaecology, Oct, Volume: 106, Issue:10
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1997The Journal of biological chemistry, Oct-17, Volume: 272, Issue:42
Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1997Endocrinology, Oct, Volume: 138, Issue:10
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)2005British journal of pharmacology, Nov, Volume: 146, Issue:5
Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.
AID1346455Rat V1A receptor (Vasopressin and oxytocin receptors)1995The EMBO journal, May-15, Volume: 14, Issue:10
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)1997Biochemical pharmacology, Jun-01, Volume: 53, Issue:11
1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.
AID1347012Rat V1B receptor (Vasopressin and oxytocin receptors)1997Biochemical pharmacology, Jun-01, Volume: 53, Issue:11
1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)2002Endocrinology, Dec, Volume: 143, Issue:12
[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1997Biochemical pharmacology, Jun-01, Volume: 53, Issue:11
1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1995The EMBO journal, May-15, Volume: 14, Issue:10
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1999British journal of obstetrics and gynaecology, Oct, Volume: 106, Issue:10
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)1998British journal of pharmacology, Dec, Volume: 125, Issue:7
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)2002Endocrinology, Dec, Volume: 143, Issue:12
[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)1998The Journal of pharmacology and experimental therapeutics, Dec, Volume: 287, Issue:3
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)2001The Journal of biological chemistry, Jul-20, Volume: 276, Issue:29
Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)2000British journal of pharmacology, Apr, Volume: 129, Issue:8
Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)1994The Journal of biological chemistry, Feb-04, Volume: 269, Issue:5
Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.
AID1346432Human V1A receptor (Vasopressin and oxytocin receptors)2000British journal of pharmacology, Apr, Volume: 129, Issue:8
Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
AID1346453Human V2 receptor (Vasopressin and oxytocin receptors)2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
AID1346469Human OT receptor (Vasopressin and oxytocin receptors)2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
AID1346460Human V1B receptor (Vasopressin and oxytocin receptors)1997Endocrinology, Oct, Volume: 138, Issue:10
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11,740)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904799 (40.88)18.7374
1990's3680 (31.35)18.2507
2000's1887 (16.07)29.6817
2010's1117 (9.51)24.3611
2020's257 (2.19)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials422 (3.44%)5.53%
Reviews800 (6.52%)6.00%
Case Studies264 (2.15%)4.05%
Observational7 (0.06%)0.25%
Other10,785 (87.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (95)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making [NCT02526914]432 participants (Anticipated)Interventional2015-10-31Not yet recruiting
Value of Copeptin Assay in Children With Febrile Seizures at Sohag University Hospital [NCT05215366]90 participants (Anticipated)Observational2022-01-07Recruiting
Efficacy of Transcervical Vasopressin Injection VersusVaginal Misoprostol During Hysteroscopic Myomectomy in Reducing Operative Blood Loss and Operation Time: A Randomized Trial. [NCT03930069]Phase 2/Phase 340 participants (Actual)Interventional2016-05-02Completed
Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients: a Comparative-effectiveness Quality Project [NCT04501861]Phase 3160 participants (Actual)Interventional2020-11-05Active, not recruiting
Prospective Randomized Double-blind Study Evaluating the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation [NCT05568160]Phase 3840 participants (Anticipated)Interventional2023-01-02Recruiting
Effects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study [NCT04053478]144 participants (Anticipated)Interventional2019-07-08Recruiting
Diagnostic Value of Copeptin Assay for Acute Coronary Syndrome Without ST-segment Elevation [NCT01334645]134 participants (Actual)Interventional2011-03-31Completed
Serum Copeptin as a Predictor of the Risk of Hyponatremia After Transurethral Prostatectomy [NCT03912766]43 participants (Actual)Observational2016-02-01Completed
Prospective, Randomized, Double-Blind, Multi-Center Trial of Low Dose Vasopressin Versus Placebo in Traumatic Shock Resuscitation [NCT00420407]Early Phase 181 participants (Actual)Interventional2007-02-28Terminated(stopped due to accrual rate)
Place of Copeptin-troponin Assay in the Elimination Diagnosis of Non-ST+ ACS in the Management of Pre-hospital and In-hospital Non-traumatic Chest Pain in Adults [NCT05902117]270 participants (Anticipated)Interventional2023-06-28Recruiting
Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension [NCT05439460]Phase 415 participants (Actual)Interventional2012-01-31Completed
Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy [NCT00799292]Phase 458 participants (Actual)Interventional2004-01-31Completed
Evaluation of Copeptin Levels in Elective Cesarean Section With Spinal and General Anesthesia and Their Relationship With Fetal Stress: Prospective Study [NCT03536910]60 participants (Actual)Interventional2018-05-01Completed
Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension [NCT01370096]Phase 23 participants (Actual)Interventional2012-02-29Terminated(stopped due to Difficulty with patient recruitment)
The Influence of Vasopressin on Observational Learning of Placebo Analgesia [NCT03446456]Phase 1/Phase 240 participants (Actual)Interventional2018-09-17Terminated(stopped due to Due to COVID-19,)
Topical Tranexamic Acid Plus Perivascular Vasopressin to Decrease Bleeding at the Time of Abdominal Myomectomy: A Double-blinded Randomized Placebo-controlled Trial [NCT03880045]100 participants (Anticipated)Interventional2019-04-01Recruiting
Serum Copeptin in Cirrhotic Patients With Spontaneous Bacterial Peritonitis [NCT05401721]89 participants (Actual)Observational2021-05-01Completed
Effects of Intranasal Oxytocin and Vasopressin on Social Behavior in Healthy Controls [NCT01296269]150 participants (Anticipated)Interventional2011-04-30Recruiting
The Effects of Vasopressin on Attention Control: An Eye-tracking Study [NCT04493554]89 participants (Actual)Interventional2020-07-28Completed
Intranasal Vasopressin Treatment in Children With Autism [NCT03204786]Phase 2/Phase 3100 participants (Anticipated)Interventional2018-02-20Recruiting
A Prospective, Randomized, Controlled Trial of Combination Vasopressin and Epinephrine to Epinephrine Only for In-Intensive Care Unit Pediatric Cardiopulmonary Resuscitation [NCT00628550]Phase 1130 participants (Anticipated)Interventional2008-04-30Completed
Value of Copeptin and the S-100b Protein Assay in Ruling Out the Diagnosis of Stroke-induced Dizziness Pattern in Emergency Departments [NCT03974464]151 participants (Actual)Observational2016-05-01Completed
COpeptin in Critically Ill Paediatric and Neonatal Intensive Care Patients and Its Association With Arterial Hypotension. A Single-centre Prospective Observational Study. [NCT03320967]170 participants (Actual)Observational2017-12-04Completed
Hemodynamic Effects of Low Doses of Arginine Vasopressin in Early Septic Shock Stage [NCT02053675]18 participants (Actual)Interventional2008-05-31Completed
The Arginine Vasopressin aXis as a Potential Therapeutic Target for Posterior REverSible Encephalopathy SyndromE (XPRESSE) [NCT04950270]24 participants (Anticipated)Observational2022-06-18Recruiting
Diluted VAsopressin During Robot-assisted Laparoscopic myomEctomy for dimiNishing Blood Loss According To the Dilution Concentration of Normal salINE: a Randomized Controlled Pilot Study [NCT04874246]39 participants (Actual)Interventional2021-05-10Completed
Phase 2 Study of Vasopressin Effects on Human Social Communication [NCT01327027]Phase 1225 participants (Actual)Interventional2011-09-30Completed
The Effects of Different Vasopressors on the Innate Immune Response During Experimental Human Endotoxemia, a Pilot Proof-of-principle Study [NCT02675868]Phase 440 participants (Actual)Interventional2016-01-31Completed
A Randomized Clinical Trial Examines the Efficacy of Intra-myometrial Local Injection of Vasopressin to Reduces the Blood Loss During Cesarean Section in Placenta Previa [NCT03725553]120 participants (Actual)Interventional2018-12-01Completed
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial [NCT05958342]Phase 21,050 participants (Anticipated)Interventional2024-03-31Not yet recruiting
"Continuous Terlipressin Versus Vasopressin Infusion in Septic Shock. A Randomized, Controlled, Pilot Trial. THE TERLIVAP STUDY" [NCT00481572]Phase 245 participants (Actual)Interventional2007-01-31Completed
AMCPR (Augmented-Medication CardioPulmonary Resuscitation) for Improving Outcome in Patient With Cardiac Arrest: Multi-center, Double-blind, Prospective Randomized Clinical Trial. [NCT03191240]Phase 2110 participants (Actual)Interventional2017-12-31Completed
Comparison of Between Norepinephrine Alone Versus Norepinephrine / Vasopressin Combination for Resuscitation in Septic Shock [NCT04302584]90 participants (Actual)Interventional2018-01-01Completed
A Randomized Double Blind Trial of Vasoactive Drugs for the Management of Shock in the ICU [NCT02118467]Phase 4836 participants (Anticipated)Interventional2014-05-31Recruiting
Cardiac Output Response to Vasopressin Infusion In Abdominal Surgery Patients Under Mechanical Ventilation: A Clinical Pharmacodynamics Study [NCT04935814]Phase 420 participants (Actual)Interventional2021-06-09Completed
Phase 2, Single-Center, Placebo-Controlled Study of the Effects of Combined Administration of Vasopressin, Methylprednisolone, and Epinephrine During Cardiopulmonary Resuscitation on Survival After Cardiac Arrest [NCT00411879]Phase 2100 participants (Actual)Interventional2006-06-30Completed
Effects of Prosocial Neuropeptides on Human Brain Function in Healthy Volunteers and Individuals With Autism Spectrum Disorders [NCT01093768]Phase 138 participants (Actual)Interventional2010-02-19Completed
Effects of Oxytocin and Vasopressin on Moral Decision Making [NCT04890470]180 participants (Actual)Interventional2021-03-02Completed
Vasopressin Receptor Agonists in Septic Shock: Effects on Microcirculation [NCT00995839]Phase 2/Phase 360 participants (Actual)Interventional2008-11-30Completed
Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest - A Randomized, Double-Blind, Placebo-Controlled Trial [NCT03640949]Phase 2/Phase 3501 participants (Actual)Interventional2018-09-17Completed
Effect of Vasopressin vs Norepinephrine on Pulmonary Oxygenation and Lung Mechanics in Patients With Hypertension Therapy During One-lung Ventilation : Preliminary Study [NCT04170751]40 participants (Anticipated)Interventional2019-11-18Recruiting
The Effect of Phenylephrine, Norepinephrine and Vasopressin on Cerebral Oxygentaion During Off Pump CABG: A Pilot Study [NCT04214145]90 participants (Actual)Interventional2020-01-07Completed
The Differential Effects of Intranasal Vasopressin and Oxytocin on Attention Control [NCT04715737]160 participants (Actual)Interventional2017-12-19Completed
Use of Vasopressin Versus Epinephrine to Reduce Hemorrhage During Myomectomy: a Randomized Controlled Trial [NCT01861015]Phase 360 participants (Actual)Interventional2013-05-31Completed
Value of Von Willebrand Factor and Copeptin Assay in Children With Febrile Seizures at Sohag University Hospital [NCT05008458]90 participants (Anticipated)Observational2021-09-01Not yet recruiting
Incidence of Hypotension Based on the Discontinuation Order of Vasopressors in the Management of Septic Shock [NCT01493102]78 participants (Actual)Interventional2011-12-31Terminated(stopped due to Futility by interim analysis)
Vasopressin and V2 Receptor in Meniere's Disease [NCT00599560]135 participants (Actual)Interventional1998-04-30Completed
Pilot Study of the Effect of Intradialytic Vasopressin Infusion on Chronic Blood Pressure Control in Hypertensive Patients With End Stage Renal Disease: A Program to Develop a Decisive, Randomized Controlled Trial [NCT01247090]Phase 212 participants (Actual)Interventional2010-10-31Completed
A Double-blind, Placebo-controlled Study Evaluating the Pharmacodynamic Effects of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) on Hypothalamic-pituitary-adrenal Axis Function in Outpatients With Major Depressive Disorder [NCT01606384]Phase 2100 participants (Actual)Interventional2006-12-31Completed
Hemodynamics and Extravascular Lung Water in Acute Lung Injury: A Prospective Randomized Controlled Multicentered Trial of Goal Directed Treatment of EVLW Versus Standard Management for the Treatment of Acute Lung Injury [NCT00624650]Phase 233 participants (Actual)Interventional2008-02-29Completed
Revisiting the Human Sweat Gland - Does Arginine Vasopressin Modulate Sweat Sodium Concentration Via the V2 Receptor? [NCT02084797]10 participants (Actual)Interventional2011-06-30Completed
The Effect of Restrictive Fluid and Vasopressin During Surgery of Burn Patients: a Randomized Clinical Trial [NCT03590873]158 participants (Anticipated)Interventional2018-07-25Recruiting
Effects of Vasopressin and Nitroglycerine in Combination on Splanchnic Blood Flow, and on Hepatic and Portal Venous Pressures in Liver Resection [NCT02993640]Early Phase 113 participants (Actual)Interventional2016-09-30Completed
A Randomized Controlled Pilot Trial of Angiotensin II Versus Vasopressin as Second-line Vasopressor in the Treatment of Septic Shock [NCT05193370]Phase 40 participants (Actual)Interventional2022-01-03Withdrawn(stopped due to Funding and protocol changes. Replaced with new pilot trial.)
Comparison of Epinephrine Associated With Vasopressin vs Epinephrine Alone in the Treatment of Out-of-Hospital Cardiac Arrests [NCT00127907]Phase 42,416 participants Interventional2004-05-31Completed
Effect of Vasopressin Injection Technique in Laparoscopic Excision of Unilateral Ovarian Endometriomas on Ovarian Reserve: Prospective Randomized Study [NCT04372836]76 participants (Anticipated)Interventional2018-10-30Recruiting
Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients [NCT00795366]96 participants (Actual)Interventional2008-09-30Completed
Assessing the Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage: a Randomized Controlled Trial [NCT03636451]Phase 3114 participants (Actual)Interventional2018-10-29Completed
Decline in Renal Concentration Ability in Lithium Treated Patients [NCT05307042]51 participants (Anticipated)Observational2022-05-31Not yet recruiting
Dopamine Versus Vasopressin for Cardiovascular Support in Extremely Low Birth Weight Infants: A Randomized, Blinded Pilot Study [NCT01318278]70 participants (Actual)Interventional2011-03-31Completed
Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial [NCT01393704]Phase 4152 participants (Actual)Interventional2011-07-31Completed
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Effects of Vasopressin V2 Receptor Antagonist on Clinical Improvement in Patients With Severe Chronic Heart Failure [NCT00032747]Phase 2338 participants (Actual)Interventional2001-08-31Completed
A Randomised, Double-blinded Multi-centre Trial Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest at the Emergency Department. (Preadmission Intravenous Vasopressin, Adrenaline Outcome Trial: PIVOT vII) [NCT00358579]Phase 3727 participants (Actual)Interventional2006-03-31Completed
Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery: a Randomized and Controlled Trial [NCT03483753]Phase 2/Phase 30 participants (Actual)Interventional2019-01-31Withdrawn(stopped due to no funding for the study)
Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation - a Cluster Randomized Controlled Phase I Trial [NCT05738148]Phase 120 participants (Anticipated)Interventional2023-11-27Recruiting
Paracervical Versus Intracervical Lidocaine for Suction Curettage: A Randomized Controlled Trial [NCT00816751]89 participants (Actual)Interventional2007-12-31Completed
Randomized Placebo-controlled Trial of Vasopressin Treatment for Social Deficits in Children With Autism [NCT01962870]Phase 268 participants (Actual)Interventional2013-12-31Completed
Comparative Prospective Study of Vasopressin and Catecholamine in Septic Shock [NCT00269685]Phase 2/Phase 320 participants Interventional2000-07-31Completed
Neuropeptides and Social Behavior [NCT01680718]Early Phase 1160 participants (Actual)Interventional2012-10-31Completed
Clinical Trials of Vasopressin for Prevention of Hypotension During Shoulder Surgery in Beach Chair Position Under General Anesthesia [NCT01687894]74 participants (Actual)Observational2012-05-31Completed
[NCT01505231]Phase 3300 participants (Anticipated)Interventional2012-01-31Recruiting
A Trial Comparing The Use Of Rectal Plus Perivascular Vasopressin With Perivascular Vasopressin Alone To Decrease Bleeding At The Time Of Myomectomy [NCT01700478]Phase 445 participants (Actual)Interventional2005-02-28Completed
Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients [NCT01718613]Phase 3250 participants (Actual)Interventional2012-11-30Completed
Comparing the Effectiveness of Misoprostol, Oxytocin, Carbetocin, Vasopressin, Bupivacaine and Epinephrine, Combined IV TXA Acid and Ethamsylate and Peri Cervical Tourniquet for the Reduction of Blood Loss During of Abdominal Myomectomy. [NCT05806307]Phase 4105 participants (Anticipated)Interventional2023-03-15Recruiting
Effect of Intranasal Vasopressin on Cooperative Behavior in Schizophrenia [NCT04190004]30 participants (Actual)Interventional2018-01-01Completed
A Multicenter, Randomized, Controlled Trial Assessing Arginine Vasopressin Versus Saline Placebo in Refractory Traumatic Hemorrhagic Shock Patients (VITRIS-study) [NCT00379522]Phase 2/Phase 364 participants (Actual)Interventional2010-07-31Completed
Arterial Pressure and Stress-Dose Steroids in In-hospital Cardiac Arrest: a Mediation Analysis of Prior Randomized Clinical Trial Data. [NCT02785224]191 participants (Anticipated)Observational2023-12-31Not yet recruiting
Biological Bases of Individual Variation in Paternal Nurturance [NCT02223429]35 participants (Actual)Interventional2014-08-31Completed
Vasopressin's Effect on Behavior and Neural Activity During Social Cognition Tasks [NCT02394054]Early Phase 184 participants (Actual)Interventional2015-01-31Completed
Incidence of Hypotension in the Weaning From Vasopressor Drugs [NCT05506319]78 participants (Anticipated)Interventional2022-04-04Recruiting
Low Dose Vasopressin for Renal Protection During Liver Transplantation [NCT00886262]18 participants (Actual)Interventional2007-07-31Completed
Copeptin; A Neuroendocrine Biomarker of COVID-19 Severity [NCT05249751]160 participants (Actual)Observational2021-06-20Completed
AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock [NCT01611935]Phase 2101 participants (Actual)Interventional2013-05-01Completed
Efficacy and Safety of Vasopressin Versus Terlipressin as a Second Vasopressor in Critically Ill Cirrhotics With Septic Shock- the VITEL-C Trial. [NCT05315557]100 participants (Anticipated)Interventional2022-04-05Not yet recruiting
Common and Differentiated Representations Between Social Exclusion and Social Separation [NCT05920707]120 participants (Anticipated)Interventional2023-04-20Recruiting
Use of Arginine Vasopressin in Early Postoperative Management After Fontan Palliation [NCT03088345]Phase 2/Phase 320 participants (Actual)Interventional2017-03-06Completed
The Biological Basis of Individual Variation in Social Cooperation [NCT01566539]707 participants (Actual)Interventional2008-04-30Completed
The Hemodynamic Effects of Vasopressin in Patients With Fontan Physiology [NCT04463394]Early Phase 128 participants (Actual)Interventional2020-08-12Completed
Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery [NCT04602767]Phase 4260 participants (Anticipated)Interventional2020-10-15Recruiting
NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock (NOVEL Trial) [NCT02454348]Phase 40 participants (Actual)Interventional2015-11-01Withdrawn(stopped due to PI left)
Influence of Argipressin on Blood Loss During Hepatic Resection; a Double-blinded, Randomized Placebo-controlled Trial (ARG-01) [NCT05293041]Phase 4248 participants (Anticipated)Interventional2022-03-27Recruiting
The Construction and Application of Therapeutic System of Intelligent Decision-Oriented Hemodynamic Organized Therapy for Shock Patients [NCT05886192]Phase 460 participants (Anticipated)Interventional2023-05-01Recruiting
Comparison of the Effect of Vasopressin, Steroid, and Epinephrine Treatment in Patients With Out-of-hospital Cardiac Arrest: Multi-center, Double Blind, Randomized, Placebo-controlled Study [NCT03317197]Phase 4834 participants (Anticipated)Interventional2018-01-01Recruiting
Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy: A Randomized Controlled Trial [NCT02377492]0 participants (Actual)Interventional2015-03-31Withdrawn(stopped due to Study never started)
Use of Vasopressin Following the Fontan Operation: Both Pilot and Multicenter Studies [NCT02975999]Phase 2/Phase 30 participants (Actual)Interventional2016-12-31Withdrawn(stopped due to Pilot study is finished, multi centered is not moving forward)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00358579 (5) [back to overview]Survival to Admission.
NCT00358579 (5) [back to overview]Survival to Hospital Discharge.
NCT00358579 (5) [back to overview]Neurological Status on Discharge or at 30 Days Post Arrest, if Not Discharged.
NCT00358579 (5) [back to overview]Neurological Status at 1 Year.
NCT00358579 (5) [back to overview]Return of Spontaneous Circulation.
NCT00420407 (2) [back to overview]Level of Vasopressin After Trauma.
NCT00420407 (2) [back to overview]The Primary Endpoint of This Study Will be Day 30 Mortality.
NCT00795366 (1) [back to overview]Time ICP >20
NCT00799292 (1) [back to overview]Estimated Blood Loss
NCT00816751 (2) [back to overview]Pain Score, as Assessed Using a 10 cm Linear Visual Analog Scale (VAS)
NCT00816751 (2) [back to overview]Gestational Age at Time of Procedure
NCT00886262 (4) [back to overview]Count of Participants Who Needed Diuretics Postoperatively
NCT00886262 (4) [back to overview]Change in Urine Output
NCT00886262 (4) [back to overview]Change in Creatinine Levels
NCT00886262 (4) [back to overview]Count of Patient Who Need Vasopressers in the Perioperative Period
NCT01247090 (1) [back to overview]Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period
NCT01318278 (13) [back to overview]Hyponatremia
NCT01318278 (13) [back to overview]Acid-base Status
NCT01318278 (13) [back to overview]All Cause Mortality
NCT01318278 (13) [back to overview]Evidence of Ischemic Changes
NCT01318278 (13) [back to overview]Grade 3 Intraventricular Hemorrhage or Worse on Head Ultrasound
NCT01318278 (13) [back to overview]Heart Rate Change From Baseline
NCT01318278 (13) [back to overview]Necrotizing Enterocolitis
NCT01318278 (13) [back to overview]Number of Subjects in Each Group Who Have Achieved an Optimal Mean Blood Pressure Value at 24 Hours of Life
NCT01318278 (13) [back to overview]Presence of Bronchopulmonary Dysplasia (BPD)
NCT01318278 (13) [back to overview]Presence of Patent Ductus Arteriosus (PDA)
NCT01318278 (13) [back to overview]Retinopathy of Prematurity Stage 3 or Higher
NCT01318278 (13) [back to overview]Urine Output
NCT01318278 (13) [back to overview]Ventilator Days
NCT01393704 (5) [back to overview]Estimating Blood Loss at the End of Myomectomy - Hematocrit Percentage
NCT01393704 (5) [back to overview]Estimating Blood Loss at the End of Myomectomy - Suction Canister Estimated Blood Loss Calculation
NCT01393704 (5) [back to overview]Estimating Blood Loss at the End of Myomectomy - Surgeon Estimated Blood Loss
NCT01393704 (5) [back to overview]Number of Participants With Peri-operative Complications
NCT01393704 (5) [back to overview]Total Operation Time
NCT01566539 (20) [back to overview]Healthy Volunteers Groups: Mean Vasopressin (AVP) Plasma Level
NCT01566539 (20) [back to overview]Empathy Task Groups: Mean Percent Signal Change in Early Visual Cortex in Response to Animation in Men
NCT01566539 (20) [back to overview]Empathy Task Groups: Mean Percent Signal Change in Early Visual Cortex in Response to Animation in Women
NCT01566539 (20) [back to overview]Healthy Volunteer Groups: Total Number of Cooperate Choices Made by Men During the Prisoners Dilemma Game
NCT01566539 (20) [back to overview]Healthy Volunteer Groups: Total Number of Cooperate Choices Made by Women During the Prisoners Dilemma Game
NCT01566539 (20) [back to overview]Healthy Volunteers Groups: Mean Oxytocin (OT) Plasma Level
NCT01566539 (20) [back to overview]Healthy Volunteers Groups: Mean Testosterone Plasma Level
NCT01566539 (20) [back to overview]Healthy Volunteers-AVP, Placebo: Mean Percent Signal Change in Left Insula in Men
NCT01566539 (20) [back to overview]Healthy Volunteers-AVP, Placebo: Mean Percent Signal Change in Left Insula in Women
NCT01566539 (20) [back to overview]Healthy Volunteers-OT, Placebo: Mean Percent Signal Change in Right Caudate Nucleus in Men
NCT01566539 (20) [back to overview]Healthy Volunteers-OT, Placebo: Mean Percent Signal Change in Right Caudate Nucleus in Women
NCT01566539 (20) [back to overview]Within Subject Group: Mean Difference in Number of Cooperate Choices Made by Male During the Prisoners Dilemma Game
NCT01566539 (20) [back to overview]Faces Task Group: Mean Approachability Rating of Faces in Women
NCT01566539 (20) [back to overview]Faces Task Groups: Mean Approachability Rating of Faces in Men
NCT01566539 (20) [back to overview]Faces Task Groups: Mean Attractiveness Rating of Faces in Men
NCT01566539 (20) [back to overview]Faces Task Groups: Mean Attractiveness Rating of Faces in Women
NCT01566539 (20) [back to overview]Faces Task Groups: Mean Percent Signal Change in Nucleus Accumbens to Faces in Men
NCT01566539 (20) [back to overview]Faces Task Groups: Mean Percent Signal Change in Nucleus Accumbens to Faces in Women
NCT01566539 (20) [back to overview]Within Subject Group: Mean Difference in Number of Cooperate Choices Made by Female During the Prisoners Dilemma Game
NCT01566539 (20) [back to overview]Within Subject Group: Mean Percent Signal Change in Left Caudate Nucleus in Men and Women
NCT01611935 (3) [back to overview]Number of Blood Products Transfused
NCT01611935 (3) [back to overview]Total Number of Complications
NCT01611935 (3) [back to overview]Need for Vasopressor Requirement Vasopressor Requirement
NCT01962870 (18) [back to overview]Change From Baseline in Body Weight After Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Parent Rated Repetitive Behavior Scale Revised (RBS-R) Scores During Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Laboratory Based Facial Emotion Recognition Abilities During Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Heart Rate After Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Clinical Global Impression (CGI) Severity, Social and Communication Scores During Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Parent Rated Pediatric Quality of Life (PedQL) Inventory Scores During Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Parent Rated Spence Children's Anxiety Scale (SCAS) During Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Plasma Vasopressin Levels During Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Reading the Mind in the Eyes Test, Child Version (RMET-child) Scores During Treatment.
NCT01962870 (18) [back to overview]Change From Baseline on the Overt Aggression Scale (OAS) During Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Blood Pressure After Treatment
NCT01962870 (18) [back to overview]Change From Baseline in Clinical Chemistry Labs (NA+, K+, Cl-) During Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Parent Rated Aberrant Behavior Checklist (ABC) Scores During Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Parent Rated Social Responsiveness Scale, 2nd Edition (SRS-2) T-Score After Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Parent Rated Vineland Adaptive Behavior Scales Second Edition (VABS-II) - Social and Communication Subscales During Treatment.
NCT01962870 (18) [back to overview]Number of Participants With Side Effects Assessed Using Parent Rated Dosage Record Treatment Emergent Symptom Scale (DOTES) Scores During Treatment
NCT01962870 (18) [back to overview]Change From Baseline in a Developmental Neuropsychological Assessment, Second Edition. (NEPSY-II) Affect Recognition Scores During Treatment.
NCT01962870 (18) [back to overview]Change From Baseline in Body Temperature After Treatment
NCT02084797 (4) [back to overview]Blood Sodium Concentration
NCT02084797 (4) [back to overview]Sweat Sodium Concentration Obtained After the Steady-state Portion of the Trial
NCT02084797 (4) [back to overview]Urine Sodium Concentration After the Steady-state Portion of the Trial
NCT02084797 (4) [back to overview]Saliva Sodium Concentration
NCT02223429 (10) [back to overview]Difference in Cry Rating Scores Between OT and Placebo
NCT02223429 (10) [back to overview]Mean Percent Signal Change in Caudate Nucleus
NCT02223429 (10) [back to overview]Mean Percent Signal Change in Primary Auditory Cortex
NCT02223429 (10) [back to overview]Mean Percent Signal Change in Right Lateral Septum
NCT02223429 (10) [back to overview]Mean Percent Signal Change in Right Ventral Striatum
NCT02223429 (10) [back to overview]Mean Percent Signal Change in the Anterior Cingulate Cortex
NCT02223429 (10) [back to overview]Mean Percent Signal Change in the Visual Cortex
NCT02223429 (10) [back to overview]Mean Percent Signal Change in Ventral Tegmental Area (VTA)
NCT02223429 (10) [back to overview]Difference in Cry Rating Scores Between AVP and Placebo
NCT02223429 (10) [back to overview]Mean Percent Signal Change in Right Medial Orbitofrontal Cortex
NCT03088345 (6) [back to overview]Liver Dysfunction as Characterized by Transaminase Levels
NCT03088345 (6) [back to overview]Renal Dysfunction as Characterized by Change in Cystatin Level
NCT03088345 (6) [back to overview]Resource Utilization Measured by Length of Stay (LOS)
NCT03088345 (6) [back to overview]Hemodynamics as Characterized by Mean Arterial Pressure
NCT03088345 (6) [back to overview]Hemodynamics as Characterized by Transpulmonary Pressure Gradient
NCT03088345 (6) [back to overview]Hemodynamics as Characterized by Vasoactive Inotrope Score (VIS)
NCT03446456 (4) [back to overview]Change in BOLD Singal in Supplementary Motor Area Compared to Whole Brain Average During the Painful Stimulation
NCT03446456 (4) [back to overview]Heating Temperature
NCT03446456 (4) [back to overview]Implicit Association Test (IAT) Response Latency Difference
NCT03446456 (4) [back to overview]Pain Ratings
NCT03636451 (4) [back to overview]Pain 10 Minutes Post Procedure
NCT03636451 (4) [back to overview]Overall Pain
NCT03636451 (4) [back to overview]Pain With Cervical Dilation
NCT03636451 (4) [back to overview]Pain With Uterine Aspiration
NCT03640949 (3) [back to overview]Number of Participants That Survived 30 Days
NCT03640949 (3) [back to overview]Number of Participants With Return of Spontaneous Circulation
NCT03640949 (3) [back to overview]Number of Participants With a Favorable Neurological Outcome at 30 Days
NCT05439460 (1) [back to overview]Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio)

Survival to Admission.

Survival to admission is defined as the presence of pulse on admission to hospital (discharged from Emergency Department and admitted to Intensive Care Units /wards). This measures the number of participants with pulse and who were admitted to hospital. (NCT00358579)
Timeframe: No specific time frame. Survival to admission refers to sustained return of spontaneous circulation until admission and transfer of care to Intensive Care Units /wards

InterventionParticipants (Number)
Adrenaline59
Vasopressin83

[back to top]

Survival to Hospital Discharge.

Survival to hospital discharge is defined as the patient leaving the hospital alive or survival to 30 days post cardiac arrest,whichever came first. This therefore measures the number of participants who was discharged alive or survived to 30 days post cardiac arrest, whichever came first. (NCT00358579)
Timeframe: at 30 days post arrest

InterventionParticipants (Number)
Adrenaline8
Vasopressin11

[back to top]

Neurological Status on Discharge or at 30 Days Post Arrest, if Not Discharged.

Neurological status is assessed by the Glasgow-Pittsburgh outcome categories, to evaluate quality of life after successful resuscitation. Good neurological status is defined as cerebral performance categories(CPC)/overall performance categories(OPC):1 and 2.CPC/OPC 1 indicates good cerebral & overall performance. CPC/OPC 2 indicates moderate cerebral & overall disability. CPC/OPC 3 indicates severe cerebral & overall disability. CPC/OPC 4 indicates coma, vegetative state. CPC/OPC 5 indicates brain dead/death. (NCT00358579)
Timeframe: at 30 days post arrest

,
InterventionParticipants (Number)
Cerebral Performance Categories 1Cerebral Performance Categories 2Overall Performance Categories 1Overall Performance Categories 2
Adrenaline5023
Vasopressin4150

[back to top]

Neurological Status at 1 Year.

Neurological status is assessed by the Glasgow-Pittsburgh outcome categories, to evaluate quality of life after successful resuscitation. Good neurological status is defined as cerebral performance categories(CPC)/overall performance categories(OPC): 1 and 2. CPC/OPC 1 indicates good cerebral & overall performance. CPC/OPC 2 indicates moderate cerebral & overall disability. CPC/OPC 3 indicates severe cerebral & overall disability. CPC/OPC 4 indicates coma, vegetative state. CPC/OPC 5 indicates brain dead/death. (NCT00358579)
Timeframe: at 1 year post arrest

,
InterventionParticipants (Number)
Cerebral Performance Categories 1Cerebral Performance Categories 2Overall Performance Categories 1Overall Performance Categories 2
Adrenaline5032
Vasopressin4131

[back to top]

Return of Spontaneous Circulation.

Return of spontaneous circulation is defined as the presence of any palpable pulse detected by manual palpation of a major artery. This is measured as number of participants who had return of spontaneous circulation during resuscitation. (NCT00358579)
Timeframe: during resuscitation

InterventionParticipants (Number)
Adrenaline106
Vasopressin119

[back to top]

Level of Vasopressin After Trauma.

Level of vasopressin 12 hours after infusion was measured for all subjects in vasopressin arm (NCT00420407)
Timeframe: 12 hours

Interventionpg/ml (Mean)
Evaluation of Vasopressin Level Following Trauma25

[back to top]

The Primary Endpoint of This Study Will be Day 30 Mortality.

Survival of a traumatic injury subject to at least 30 days after admission to the emergency room. (NCT00420407)
Timeframe: 30 days

InterventionParticipants (Number)
Normal Saline11
Vasopressin13

[back to top]

Time ICP >20

The number of hours that participants remained with intracranial pressure above 20 mmHg (NCT00795366)
Timeframe: The number of hours during the first 5 days of intracranial pressure monitoring

InterventionHours (Mean)
AVP, Arginine Vasopressin1.7
Standard Catecholamine.9

[back to top]

Estimated Blood Loss

Estimated blood loss as mL (NCT00799292)
Timeframe: Duration of vaginal hysterectomy

InterventionmL (Mean)
No Injection266.4
Injection of Vasopressin145.3

[back to top]

Pain Score, as Assessed Using a 10 cm Linear Visual Analog Scale (VAS)

VAS on a scale of 1 to 10 with 1 being lowest pain and 10 highest amount of pain (NCT00816751)
Timeframe: at completion of procedure

Interventionunits on a scale (Mean)
Paracervical Block4.25
Intracervical Block3.97

[back to top]

Gestational Age at Time of Procedure

(NCT00816751)
Timeframe: At the time of the procedure

InterventionDays (Mean)
Paracervical Block51
Intracervical Block54

[back to top]

Count of Participants Who Needed Diuretics Postoperatively

(NCT00886262)
Timeframe: 48 hours

InterventionParticipants (Count of Participants)
Vasopressin4
Normal Saline Placebo1

[back to top]

Change in Urine Output

(NCT00886262)
Timeframe: 24 hours to 48 hours postop

InterventionmL (Mean)
Vasopressin1353
Normal Saline Placebo731

[back to top]

Change in Creatinine Levels

(NCT00886262)
Timeframe: baseline to 48 hours postop

InterventionMG/DL (Mean)
Vasopressin0.5
Normal Saline Placebo0.55

[back to top]

Count of Patient Who Need Vasopressers in the Perioperative Period

(NCT00886262)
Timeframe: 48 hours

InterventionParticipants (Count of Participants)
Vasopressin3
Normal Saline Placebo4

[back to top]

Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period

This is designed to measure if the administration of intradialytic AVP will result in change in systolic blood pressure. (NCT01247090)
Timeframe: Baseline and Two Weeks

Interventionmm Hg (Mean)
Very Low Dose-1.5
Low Dose-3.7
Placebo-0.4

[back to top]

Hyponatremia

(NCT01318278)
Timeframe: 96 hours or until medication completely stopped

Interventionparticipants (Number)
Dopamine Treatment3
Vasopressin Treatment3
Comparison Arm11

[back to top]

Acid-base Status

(NCT01318278)
Timeframe: 96 hours or until hypotension resolved and medication completely stopped

InterventionpH (Mean)
Dopamine Treatment7.18
Vasopressin Treatment7.2
Comparison Group7.25

[back to top]

All Cause Mortality

(NCT01318278)
Timeframe: admission to hospital discharge, up to 15 months

Interventionparticipants (Number)
Dopamine Treatment2
Vasopressin Treatment4
Comparison Arm10

[back to top]

Evidence of Ischemic Changes

Physical examinations were done on at least a twice daily basis to evaluate for any ischemic lesions (especially on the limbs) of all subjects. The presence of any lesion considered to be due to ischemia would have been reported in this data. (NCT01318278)
Timeframe: 96 hours or until medication completely stopped

Interventionparticipants (Number)
Dopamine Treatment0
Vasopressin Treatment0
Comparison Arm0

[back to top]

Grade 3 Intraventricular Hemorrhage or Worse on Head Ultrasound

(NCT01318278)
Timeframe: Until hospital discharge, up to 15 months

Interventionparticipants (Number)
Dopamine Treatment3
Vasopressin Treatment3
Comparison Arm6

[back to top]

Heart Rate Change From Baseline

Heart rate change from baseline during study drug administration (NCT01318278)
Timeframe: 96 hours or until hypotension completely resolved and medications stopped

Interventionbeats per minute (Mean)
Dopamine Treatment31
Vasopressin Treatment0

[back to top]

Necrotizing Enterocolitis

(NCT01318278)
Timeframe: until hospital discharge, up to 12 weeks

Interventionparticipants (Number)
Dopamine Treatment0
Vasopressin Treatment1
Comparison Arm2

[back to top]

Number of Subjects in Each Group Who Have Achieved an Optimal Mean Blood Pressure Value at 24 Hours of Life

Optimal mean blood pressure (OMBP) will be defined as either a 10% increase in mean blood pressure value or a 2-3 mmHg rise in mean blood pressure value AND an improvement in tissue perfusion as demonstrated by a resolution in the specified clinical symptom (designated upon enrollment) within 4-6 hours of having reached OMBP (NCT01318278)
Timeframe: 24 hours of life

Interventionparticipants (Number)
Dopamine Treatment9
Vasopressin Treatment9

[back to top]

Presence of Bronchopulmonary Dysplasia (BPD)

Infants were evaluated for oxygen need at 36 weeks postmenstrual age. If they required supplemental oxygen, they were diagnosed with BPD (NCT01318278)
Timeframe: 36 weeks postmenstrual age

Interventionparticipants (Number)
Dopamine Treatment8
Vasopressin Treatment4
Comparison Arm31

[back to top]

Presence of Patent Ductus Arteriosus (PDA)

(NCT01318278)
Timeframe: until hospital discharge, up to 12 weeks

Interventionparticipants (Number)
Dopamine Treatment5
Vasopressin Treatment6
Comparison Arm34

[back to top]

Retinopathy of Prematurity Stage 3 or Higher

"All subjects were followed by an ophthalmologist with initial exam at 4-6 weeks of age. The Stages describe the ophthalmoscopic findings at the junction between the vascularized and avascular retina. Each subject is followed until cleared by ophthalmology. For this outcome measure, the most severe stage of disease was used in analysis.~Stage 1 is a faint demarcation line. Stage 2 is an elevated ridge. Stage 3 is extraretinal fibrovascular proliferation (neovascularization). Stage 4 is sub-total retinal detachment. Stage 5 is total retinal detachment. Stages 1 and 2 do not lead to blindness. However, they can progress to the more severe stages." (NCT01318278)
Timeframe: Until hospital discharge, up to 15 months

Interventionparticipants (Number)
Dopamine Treatment3
Vasopressin Treatment2
Comparison Arm4

[back to top]

Urine Output

(NCT01318278)
Timeframe: 96 hours or until hypotension resolved and medication completely stopped

Interventionml/kg/hr (Mean)
Dopamine Treatment4.4
Vasopressin Treatment3.5
Comparison Arm3.9

[back to top]

Ventilator Days

(NCT01318278)
Timeframe: Until hospital discharge, up to 15 months

Interventiondays (Median)
Dopamine Treatment52
Vasopressin Treatment45.5
Comparison Arm17.5

[back to top]

Estimating Blood Loss at the End of Myomectomy - Hematocrit Percentage

To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome. Pre and post-operative hematocrit change (%) was one of these measurement methods. (NCT01393704)
Timeframe: 5 minutes post-operatively

Interventionhematocrit percentage (Mean)
High Volume Dilute Vasopressin-4.4
Low Volume Dilute Vasopressin-4.0

[back to top]

Estimating Blood Loss at the End of Myomectomy - Suction Canister Estimated Blood Loss Calculation

To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome. Objective calculation of blood loss via the measurement of suction canister fluid (ml) was one of these. The calculation for estimated blood loss will be as follows: EBL = [total suction canister volume] - [volume of irrigation used] - [volume of vasopressin solution injected /2]. (NCT01393704)
Timeframe: 5 minutes post-operatively

Interventionmillileters (Mean)
High Volume Dilute Vasopressin178
Low Volume Dilute Vasopressin198

[back to top]

Estimating Blood Loss at the End of Myomectomy - Surgeon Estimated Blood Loss

To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome: Subjective surgeon's estimate of blood loss (ml) was one measurement method. (NCT01393704)
Timeframe: 5 minutes post-operatively

Interventionmillileters (Mean)
High Volume Dilute Vasopressin106.2
Low Volume Dilute Vasopressin119

[back to top]

Number of Participants With Peri-operative Complications

Intra or post-operative complications (including but not limited to need for blood transfusion or adverse effect related to Vasopressin). (NCT01393704)
Timeframe: 8 weeks postoperatively

InterventionParticipants (Count of Participants)
High Volume Dilute Vasopressin9
Low Volume Dilute Vasopressin10

[back to top]

Total Operation Time

Time from incision to end of surgery (NCT01393704)
Timeframe: 5 minutes postoperatively

Interventionminutes (Mean)
High Volume Dilute Vasopressin176.8
Low Volume Dilute Vasopressin165.5

[back to top]

Healthy Volunteers Groups: Mean Vasopressin (AVP) Plasma Level

Peripheral levels of AVP will be assessed via assay of plasma collected. (NCT01566539)
Timeframe: Visit 1 (Up to 3 Hours)

Interventionpg/ml (Mean)
Healthy Volunteers - Intranasal Vasopressin (AVP)4.5
Healthy Volunteers - Intranasal Oxytocin (OT)3.5
Healthy Volunteers - Intranasal Placebo3.1

[back to top]

Empathy Task Groups: Mean Percent Signal Change in Early Visual Cortex in Response to Animation in Men

The effect of the drug treatment will be assessed by determining differences in brain activation between OT and PL group when participants are viewing animations. (NCT01566539)
Timeframe: Visit 1 (40-75 Minutes Post-Intervention), Visit 2 (Up to 1 Month)

Interventionpercent signal change (Mean)
Empathy Task - Oxytocin (OT)-.429
Empathy Task - Placebo-.382

[back to top]

Empathy Task Groups: Mean Percent Signal Change in Early Visual Cortex in Response to Animation in Women

The effect of the drug treatment will be assessed by determining differences in brain activation between OT and PL group when participants are viewing animations. (NCT01566539)
Timeframe: Visit 1 (40-75 Minutes Post-Intervention), Visit 2 (Up to 1 Month)

Interventionpercent signal change (Mean)
Empathy Task - Oxytocin (OT)-.910
Empathy Task - Placebo-.377

[back to top]

Healthy Volunteer Groups: Total Number of Cooperate Choices Made by Men During the Prisoners Dilemma Game

"The effect of the drug treatments will be assessed by determining the number of cooperative choices made during the prisoner's dilemma game. Participants may make two choices that are considered cooperative. The higher the total number, the more cooperative choices made." (NCT01566539)
Timeframe: Visit 1 (40-100 Minutes Post-Intervention)

Interventionnumber of choices (Mean)
Healthy Volunteers - Intranasal Vasopressin (AVP)15.71
Healthy Volunteers - Intranasal Oxytocin (OT)16.18
Healthy Volunteers - Intranasal Placebo17.68

[back to top]

Healthy Volunteer Groups: Total Number of Cooperate Choices Made by Women During the Prisoners Dilemma Game

"The effect of the drug treatments will be assessed by determining the number of cooperative choices made during the prisoner's dilemma game. Participants may make two choices that are considered cooperative. The higher the total number, the more cooperative choices made." (NCT01566539)
Timeframe: Visit 1 (40-100 Minutes Post-Intervention)

Interventionnumber of choices (Mean)
Healthy Volunteers - Intranasal Vasopressin (AVP)15.84
Healthy Volunteers - Intranasal Oxytocin (OT)18.14
Healthy Volunteers - Intranasal Placebo16.92

[back to top]

Healthy Volunteers Groups: Mean Oxytocin (OT) Plasma Level

Peripheral levels of OT will be assessed via assay of plasma collected. (NCT01566539)
Timeframe: Visit 1 (Up to 3 Hours)

Interventionpg/ml (Mean)
Healthy Volunteers - Intranasal Vasopressin (AVP)120.6
Healthy Volunteers - Intranasal Oxytocin (OT)134.7
Healthy Volunteers - Intranasal Placebo129.4

[back to top]

Healthy Volunteers Groups: Mean Testosterone Plasma Level

Peripherals levels of testosterone will be assessed via assay of plasma collected. (NCT01566539)
Timeframe: Visit 1 (Up to 3 Hours)

Interventionng/dl (Mean)
Healthy Volunteers - Intranasal Vasopressin (AVP)214.92
Healthy Volunteers - Intranasal Oxytocin (OT)475.82
Healthy Volunteers - Intranasal Placebo437.99

[back to top]

Healthy Volunteers-AVP, Placebo: Mean Percent Signal Change in Left Insula in Men

The effect of the drug treatment will be assessed by determining differences in brain activation between AVP and placebo groups in the left insula region during reciprocated cooperation in Prisoner Dilemma game while undergoing an fMRI scan. (NCT01566539)
Timeframe: Visit 1 (40-100 Minutes Post-Intervention)

Interventionpercent signal change (Mean)
Healthy Volunteers - Intranasal Vasopressin (AVP)0.13
Healthy Volunteers - Intranasal Placebo-0.02

[back to top]

Healthy Volunteers-AVP, Placebo: Mean Percent Signal Change in Left Insula in Women

The effect of the drug treatment will be assessed by determining differences in brain activation between AVP and placebo groups in the left insula during reciprocated cooperation in Prisoner Dilemma game while undergoing an fMRI scan. (NCT01566539)
Timeframe: Visit 1 (40-100 Minutes Post-Intervention)

Interventionpercent signal change (Mean)
Healthy Volunteers - Intranasal Vasopressin (AVP)-0.05
Healthy Volunteers - Intranasal Placebo0.10

[back to top]

Healthy Volunteers-OT, Placebo: Mean Percent Signal Change in Right Caudate Nucleus in Men

The effect of the drug treatment will be assessed by determining differences in brain activation between OT and placebo groups in the right caudate nucleus region during reciprocated cooperation in Prisoner Dilemma game while undergoing an fMRI scan. (NCT01566539)
Timeframe: Visit 1 (40-100 Minutes Post-Intervention)

Interventionpercent signal change (Mean)
Healthy Volunteers - Intranasal Oxytocin (OT)0.21
Healthy Volunteers - Intranasal Placebo0.07

[back to top]

Healthy Volunteers-OT, Placebo: Mean Percent Signal Change in Right Caudate Nucleus in Women

The effect of the drug treatment will be assessed by determining differences in brain activation between OT and placebo groups in the right caudate nucleus region during reciprocated cooperation in Prisoner Dilemma game while undergoing an fMRI scan. (NCT01566539)
Timeframe: Visit 1 (40-100 Minutes Post-Intervention)

Interventionpercent signal change (Mean)
Healthy Volunteers - Intranasal Oxytocin (OT)0.04
Healthy Volunteers - Intranasal Placebo0.15

[back to top]

Within Subject Group: Mean Difference in Number of Cooperate Choices Made by Male During the Prisoners Dilemma Game

"The effect of the drug treatments will be assessed by determining the number of cooperative choices made during the prisoner's dilemma game. Participants may make two choices that are considered cooperative. The higher the total number, the more cooperative choices made." (NCT01566539)
Timeframe: Visit 1 (30-75 Minutes Post-Intervention), Visit 2 (Up to 2 Weeks)

Interventionnumber of choices (Mean)
Within Subject Group-1.10

[back to top]

Faces Task Group: Mean Approachability Rating of Faces in Women

Approachability is rated by a study specific seven point scale where -3 indicates threatening and unapproachable and +3 indicates friendly and approachable. Participants will rate same-sex and other-sex faces. The effect of the drug treatment will be assessed by determining differences in approachability ratings between AVP and PL group when participants are viewing same-sex faces, and when participants are viewing other-sex faces. (NCT01566539)
Timeframe: Visit 1 (30-75 Minutes Post-Intervention), Visit 2 (Up to 7 Days)

,
Interventionunits on a scale (Mean)
viewing same-sex faces scan 1viewing other-sex faces scan 1viewing same-sex faces scan 2viewing other-sex faces scan 2
Faces Task - Placebo0.210.280.230.22
Faces Task - Vasopressin (AVP)0.37-0.040.370.12

[back to top]

Faces Task Groups: Mean Approachability Rating of Faces in Men

Approachability is rated by a study specific seven point scale where -3 indicates threatening and unapproachable and +3 indicates friendly and approachable. Participants will rate same-sex and other-sex faces. The effect of the drug treatment will be assessed by determining differences in approachability ratings between AVP and PL group when participants are viewing same-sex faces, and when participants are viewing other-sex faces. (NCT01566539)
Timeframe: Visit 1 (30-75 Minutes Post-Intervention), Visit 2 (Up to 7 Days)

,
Interventionunits on a scale (Mean)
viewing same-sex faces scan 1viewing other-sex faces scan 1viewing same-sex faces scan 2viewing other-sex faces scan 2
Faces Task - Placebo-0.060.810.250.89
Faces Task - Vasopressin (AVP)0.311.000.781.19

[back to top]

Faces Task Groups: Mean Attractiveness Rating of Faces in Men

Attractiveness is rated by a study specific seven point scale where -3 indicates least attractive and +3 indicates most attractive. Participants will rate same-sex and other-sex faces. The effect of the drug treatment will be assessed by determining differences in attractiveness ratings between AVP and PL group when participants are viewing same-sex faces, and when participants are viewing other-sex faces. (NCT01566539)
Timeframe: Visit 1 (30-75 Minutes Post-Intervention), Visit 2 (Up to 7 Days)

,
Interventionunits on a scale (Mean)
viewing same-sex faces scan 1viewing other-sex faces scan 1viewing same-sex faces scan 2viewing other-sex faces scan 2
Faces Task - Placebo-0.061.60-0.081.43
Faces Task - Vasopressin (AVP)0.351.790.521.70

[back to top]

Faces Task Groups: Mean Attractiveness Rating of Faces in Women

Attractiveness is rated by a study specific seven point scale where -3 indicates least attractive and +3 indicates most attractive. Participants will rate same-sex and other-sex faces. The effect of the drug treatment will be assessed by determining differences in attractiveness ratings between AVP and PL group when participants are viewing same-sex faces, and when participants are viewing other-sex faces. (NCT01566539)
Timeframe: Visit 1 (30-75 Minutes Post-Intervention), Visit 2 (Up to 7 Days)

,
Interventionunits on a scale (Mean)
viewing same-sex faces scan 1viewing other-sex faces scan 1viewing same-sex faces scan 2viewing other-sex faces scan 2
Faces Task - Placebo1.020.610.820.28
Faces Task - Vasopressin (AVP)1.560.551.290.53

[back to top]

Faces Task Groups: Mean Percent Signal Change in Nucleus Accumbens to Faces in Men

The effect of the drug treatment will be assessed by determining differences in brain activation between AVP and PL group when participants are viewing same-sex faces, and when participants are viewing other-sex faces. (NCT01566539)
Timeframe: Visit 1 (30-75 Minutes Post-Intervention), Visit 2 (Up to 7 Days)

,
Interventionpercent signal change (Mean)
viewing same-sex facesviewing other-sex faces
Faces Task - Placebo-0.14-0.13
Faces Task - Vasopressin (AVP)0.030.14

[back to top]

Faces Task Groups: Mean Percent Signal Change in Nucleus Accumbens to Faces in Women

The effect of the drug treatment will be assessed by determining differences in brain activation between AVP and PL group when participants are viewing same-sex faces, and when participants are viewing other-sex faces. (NCT01566539)
Timeframe: Visit 1 (30-75 Minutes Post-Intervention), Visit 2 (Up to 7 Days)

,
Interventionpercent signal change (Mean)
viewing same-sex facesviewing other-sex faces
Faces Task - Placebo0.120.13
Faces Task - Vasopressin (AVP)-0.080.003

[back to top]

Within Subject Group: Mean Difference in Number of Cooperate Choices Made by Female During the Prisoners Dilemma Game

"The effect of the drug treatments will be assessed by determining the number of cooperative choices made during the prisoner's dilemma game. Participants may make two choices that are considered cooperative. The higher the total number, the more cooperative choices made." (NCT01566539)
Timeframe: Visit 1 (30-75 Minutes Post-Intervention), Visit 2 (Up to 2 Weeks)

Interventionnumber of choices (Mean)
Oxytocin treatmentPlacebo treatment
Within Subject Group16.1315.53

[back to top]

Within Subject Group: Mean Percent Signal Change in Left Caudate Nucleus in Men and Women

The effect of the drug will be assessed by determining changes in brain activation between the visit where the participant received drug and the visit where the participant received PL in the right caudate during reciprocated cooperation in Prisoner Dilemma game while undergoing an fMRI scan. (NCT01566539)
Timeframe: Visit 1 (30-75 Minutes Post-Intervention), Visit 2 (Up to 2 Weeks)

Interventionpercent signal change (Mean)
Oxytocin treatment in menPlacebo treatment in menOxytocin treatment in womenPlacebo treatment in women
Within Subject Group0.210.190.060.10

[back to top]

Number of Blood Products Transfused

Cumulative number of units of blood products, including packed red blood cells, plasma and platelets measured in liters (NCT01611935)
Timeframe: 48 hours following the initiation of therapy

InterventionLitre (Median)
Vasopressin1.7
Normal Saline3.0

[back to top]

Total Number of Complications

Variables will include intra-abdominal hypertension, open abdomen free days, ventilator-free days, ICU-free days, development of ARDS, development of renal failure, development of multiple organ failure, volume of crystalloid requirement within 48 hours post injury, and mortality. (NCT01611935)
Timeframe: 30 days post injury

InterventionComplications (Number)
Vasopressin69
Normal Saline98

[back to top]

Need for Vasopressor Requirement Vasopressor Requirement

total dose of vasopressors (epinephrine, norepinephrine, neosynephrine, etc) received by patient within 48 hours converted to norepinephrine equivalents (g) range in our study was from 0 gm to a max of 53 gm (NCT01611935)
Timeframe: 48 hours following the initiation of therapy

InterventionNorepinephrine equivalents (g) (Median)
Vasopressin0.6
Normal Saline1.5

[back to top]

Change From Baseline in Body Weight After Treatment.

(NCT01962870)
Timeframe: Baseline; Week 4

Interventionkilograms (Least Squares Mean)
Placebo0.2
Vasopressin0.3

[back to top]

Change From Baseline in Parent Rated Repetitive Behavior Scale Revised (RBS-R) Scores During Treatment.

Higher scores on the Repetitive Behavior Scale- Revised mean higher levels of repetitive and restricted behaviors. (Raw Score Total Range: 0 - 129) (NCT01962870)
Timeframe: Baseline; Week 4

Interventionunits on a scale (Mean)
Placebo21.3
Vasopressin17.2

[back to top]

Change From Baseline in Laboratory Based Facial Emotion Recognition Abilities During Treatment.

Higher scores mean better facial emotion recognition abilities. Lower scores mean worse facial emotion recognition abilities (Range: 0-42). (NCT01962870)
Timeframe: Baseline; Week 4

Interventionunits on a scale (Mean)
Placebo-7.19
Vasopressin3.10

[back to top]

Change From Baseline in Heart Rate After Treatment.

Sitting heart rate (beats per minute). (NCT01962870)
Timeframe: Baseline; Week 4

InterventionBeats per minute (Least Squares Mean)
Placebo7.5
Vasopressin1.9

[back to top]

Change From Baseline in Clinical Global Impression (CGI) Severity, Social and Communication Scores During Treatment.

Higher Scores on the CGI severity scale mean more greater social and communication deficits (Range 1-7) (NCT01962870)
Timeframe: Baseline; Week 4

Interventionunits on a scale (Least Squares Mean)
Placebo0.712
Vasopressin0.873

[back to top]

Change From Baseline in Parent Rated Pediatric Quality of Life (PedQL) Inventory Scores During Treatment.

Higher scores mean better quality of life and lower scores mean worse quality of life (Range: Minimum=0; Maximum=100). (NCT01962870)
Timeframe: Baseline; Week 4

,
Interventionunits on a scale (Mean)
BaselineWeek 4
Placebo57.1465.96
Vasopressin64.5374.52

[back to top]

Change From Baseline in Parent Rated Spence Children's Anxiety Scale (SCAS) During Treatment.

Scale measuring severity of anxiety symptoms. Higher scores mean higher levels of anxiety, lower scores mean lower levels of anxiety. (Raw Score Range: 0 - 114) (NCT01962870)
Timeframe: Baseline; Week 4

Interventionunits on a scale (Least Squares Mean)
Placebo9.14
Vasopressin17.9

[back to top]

Change From Baseline in Plasma Vasopressin Levels During Treatment.

There are no clinical laboratory tests that establish a normative range for vasopressin. Measurements prior to treatment were intended to evaluate vasopressin level as a predictor of response. Plasma vasopressin levels post treatment were not quantified. Baseline vasopressin levels are included in the outcome data below. (NCT01962870)
Timeframe: Baseline

Interventionpg/ml (Mean)
Placebo1.28
Vasopressin1.32

[back to top]

Change From Baseline in Reading the Mind in the Eyes Test, Child Version (RMET-child) Scores During Treatment.

Higher scores mean better ability to read emotions and lower scores mean worse ability to read emotions. Range 0-28. (NCT01962870)
Timeframe: Baseline; Week 4

Interventionunits on a scale (Mean)
Placebo-1.28
Vasopressin4.04

[back to top]

Change From Baseline on the Overt Aggression Scale (OAS) During Treatment.

Count of participants reporting an increase of aggression during treatment compared to baseline (pretreatment). (NCT01962870)
Timeframe: Baseline through Week 4

InterventionParticipants (Count of Participants)
Placebo1
Vasopressin1

[back to top]

Change From Baseline in Blood Pressure After Treatment

Sitting Systolic and Diastolic blood pressure. (NCT01962870)
Timeframe: Baseline; Week 4

,
InterventionmmHG (Least Squares Mean)
Change from Baseline in Systolic Blood PressureChange from Baseline in Diastolic Blood Pressure
Placebo-1.1-1.8
Vasopressin5.53.2

[back to top]

Change From Baseline in Clinical Chemistry Labs (NA+, K+, Cl-) During Treatment.

Clinical chemistry labs(sodium, potassium, chloride) (NCT01962870)
Timeframe: Baseline; Week 4

,
Interventionmmol/L (Least Squares Mean)
Change From Baseline in SodiumChange from Baseline in PotassiumChange from Baseline on Chloride
Placebo0.150.06-0.31
Vasopressin0.240.151.0

[back to top]

Change From Baseline in Parent Rated Aberrant Behavior Checklist (ABC) Scores During Treatment.

Higher scores indicate more symptoms, lower scores indicate fewer symptoms. Irritability scores can range from 0-45. Lethargy scores can range from 0-48. Stereotypy scores can range from 0-21. Hyperactivity scores can range from 0-48. Inappropriate speech scores can from 0-12. (NCT01962870)
Timeframe: Baseline; Week 4

,
Interventionunits on a scale (Mean)
Irritability BaselineIrritability Week 4Lethargy BaselineLethargy Week 4Stereotypy BaselineStereotypy Week 4Hyperactivity BaselineHyperactivity Week 4Inappropriate Speech BaselineInappropriate Speech Week 4
Placebo14.008.3814.7712.775.084.5421.3814.544.623.69
Vasopressin8.296.2410.767.415.183.5316.0012.293.943.41

[back to top]

Change From Baseline in Parent Rated Social Responsiveness Scale, 2nd Edition (SRS-2) T-Score After Treatment.

Social Responsiveness Scale, 2nd Edition (SRS) scores measure social abilities with lower scores meaning better social abilities. (T-Score Range: 37- above 90 ) (NCT01962870)
Timeframe: Baseline; Week 4

Interventionunits on a scale (Least Squares Mean)
Placebo10.8
Vasopressin17.6

[back to top]

Change From Baseline in Parent Rated Vineland Adaptive Behavior Scales Second Edition (VABS-II) - Social and Communication Subscales During Treatment.

Higher Social Standard Score means better social skills, lower Social Standard Score means worse social skills. Higher Communication Standard Score means better communication skills, lower Communication Standard Score means worse communication skills. Standard Scores can range from 20 to 160. (NCT01962870)
Timeframe: Baseline; Week 4

,
Interventionunits on a scale (Mean)
Baseline Social Standard ScoreWeek 4 Social Standard ScoreBaseline Communication Standard ScoreWeek 4 Communication Standard Score
Placebo61.3362.2575.6777.40
Vasopressin71.0879.6774.7781.12

[back to top]

Number of Participants With Side Effects Assessed Using Parent Rated Dosage Record Treatment Emergent Symptom Scale (DOTES) Scores During Treatment

Dosage Record Treatment Emergent Symptom Scale (DOTES) side effects reported by parents during 4-weeks of treatment. Participant Counts are used. (NCT01962870)
Timeframe: Baseline through Week 4

,
Interventionparticipants (Number)
FeverCoughBody AcheExcitement/AgitationInsomniaIncreased Motor ActivityDepressive AffectHeadacheDrowsinessDecreased Motor ActivityAggressionAkathisiaHead BangingDizzinessLethargy/TirednessNasal CongestionDry MouthBlurred VisionEar InfectionRunny NoseSore ThroatCold SoreDecreased AppetiteNausea/VomitingConstipationDiarrheaIncreased UrinationBed WettingSkin RashBug BiteSkin Burn
Placebo1001101032100114311111520110101
Vasopressin2110442211111003110000421011110

[back to top]

Change From Baseline in a Developmental Neuropsychological Assessment, Second Edition. (NEPSY-II) Affect Recognition Scores During Treatment.

"Higher Affect Recognition scores mean better affect recognition abilities, lower Affect Recognition scores mean worse affect recognition abilities.~Scores can range from 1 to 19." (NCT01962870)
Timeframe: Baseline; Week 4

Interventionunits on a scale (Least Squares Mean)
Placebo-2.58
Vasopressin0.094

[back to top]

Change From Baseline in Body Temperature After Treatment

(NCT01962870)
Timeframe: Baseline; Week 4

InterventionDegrees (Farenheit) (Least Squares Mean)
Placebo-0.2
Vasopressin0.2

[back to top]

Blood Sodium Concentration

Measurement of blood sodium concentration will determine if normonatremia (blood sodium concentrations within the normal physiological range of 135-145mmol/L) were maintained throughout the trial with appropriate fluid intake during the V2R antagonist, agonist and placebo intervention trials. (NCT02084797)
Timeframe: 4 study trials (4 weeks)

InterventionmEq/L (Mean)
PlaceboV2R AgonistV2R Antagonist
1/Placebo, V2R Agonist, V2R Antagonist143.6144.3145.9

[back to top]

Sweat Sodium Concentration Obtained After the Steady-state Portion of the Trial

Changes in sweat sodium concentration will parallel changes in urine sodium concentration with use of the V2R antagonist, agonist and placebo if the primary hypothesis is true (sweat sodium is regulated by the V2R, similar to how urine sodium is regulated by principle cells located within in the kidney collecting duct) (NCT02084797)
Timeframe: 4 study trials (4 weeks)

InterventionmEq/L (Mean)
PlaceboV2R AgonistV2R Antagonist
1/Placebo, V2R Agonist, V2R Antagonist80.176.884.7

[back to top]

Urine Sodium Concentration After the Steady-state Portion of the Trial

Changes in urine sodium concentration after use of the V2R antagonist, agonist and placebo interventions will verify whether or not pharmacologic activation or inhibition was successfully induced. (NCT02084797)
Timeframe: 4 study trials (4 weeks)

InterventionmEq/L (Mean)
PlaceboV2R AgonistV2R Antagonist
1/Placebo, V2R Agonist, V2R Antagonist82.089.316.4

[back to top]

Saliva Sodium Concentration

Measurement of salivary sodium concentration will allow us to determine if the V2R antagonist, agonist and placebo interventions activate aquaporin-5 (AQP5) water channels that are also located in sweat glands. If the V2R acts on the sweat glands through AQP5, there should be parallel changes in sweat, urine and saliva sodium concentrations with each pharmaceutical intervention. (NCT02084797)
Timeframe: 4 trials (4 weeks)

InterventionmEq/L (Mean)
PlaceboV2R AgonistV2R Antagonist
1/Placebo, V2R Agonist, V2R Antagonist20.528.131.0

[back to top]

Difference in Cry Rating Scores Between OT and Placebo

"The effect of the drug will be assessed by analyzing the differences between ratings of infant cries under OT and placebo treatment on a 7-point likert scale. Sixteen adjectives will be used to describe two different cries. Participants will rate each cry from 1-7 where one represents not at all and 7 represents extremely. Difference is defined as OT minus placebo scores." (NCT02223429)
Timeframe: Baseline, Visit 2 (Up to 10 days)

,
Interventionunits on a scale (Mean)
Cry 1 GratingCry 1 UrgentCry 1 PiercingCry 1 AversiveCry 1 CompellingCry 1 ManipulativeCry 1 SpoiledCry 1 IrritatedCry 1 SympatheticCry 1 AlarmedCry 1 AngryCry 1 UpsetCry 1 CompassionateCry 1 DistressedCry 1 AnnoyedCry 1 TenderCry 2 GratingCry 2 UrgentCry 2 PiercingCry 2 AversiveCry 2 CompellingCry 2 ManipulativeCry 2 SpoiledCry 2 IrritatedCry 2 SypmatheticCry 2 AlarmedCry 2 AngryCry 2 UpsetCry 2 CompassionateCry 2 DistressedCry 2 AnnoyedCry 2 Tender
Oxytocin3.714.294.293.574.572.862.143.074.714.212.433.074.863.572.433.793.434.933.713.505.212.432.002.215.864.361.792.865.713.362.004.50
Placebo4.644.864.363.365.002.292.073.294.434.072.573.295.143.642.433.643.794.434.004.075.142.362.002.365.644.571.792.575.433.861.934.79

[back to top]

Mean Percent Signal Change in Caudate Nucleus

The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI). (NCT02223429)
Timeframe: Baseline, Visit 2 (Up to 10 days)

InterventionPercent signal change (Mean)
Oxytocin0.85
Placebo-0.27

[back to top]

Mean Percent Signal Change in Primary Auditory Cortex

The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI). Changes will be assessed in the OT group only per protocol. (NCT02223429)
Timeframe: Baseline, Visit 2 (Up to 10 days)

InterventionPercent signal change (Mean)
Oxytocin0.10
Placebo0.10

[back to top]

Mean Percent Signal Change in Right Lateral Septum

The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between AVP treatment and placebo treatments (AVP-PL) from functional magnetic resonance imaging (fMRI). Changes will be assessed in the AVP group only per protocol. (NCT02223429)
Timeframe: Baseline, Visit 2 (Up to 10 days)

InterventionPercent signal change (Mean)
Vasopressin (AVP)0.19
Placebo0.36

[back to top]

Mean Percent Signal Change in Right Ventral Striatum

The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI). Changes will be assessed in the OT group only per protocol. (NCT02223429)
Timeframe: Baseline, Visit 2 (Up to 10 days)

InterventionPercent signal change (Mean)
Oxytocin-1.28
Placebo-0.81

[back to top]

Mean Percent Signal Change in the Anterior Cingulate Cortex

The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI). (NCT02223429)
Timeframe: Baseline, Visit 2 (Up to 10 days)

InterventionPercent signal change (Mean)
Oxytocin0.27
Placebo-0.39

[back to top]

Mean Percent Signal Change in the Visual Cortex

The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI). (NCT02223429)
Timeframe: Baseline, Visit 2 (Up to 10 days)

InterventionPercent signal change (Mean)
Oxytocin0.83
Placebo0.10

[back to top]

Mean Percent Signal Change in Ventral Tegmental Area (VTA)

The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI). Changes will be assessed in the OT group only per protocol. (NCT02223429)
Timeframe: Baseline, Visit 2 (Up to 10 days)

InterventionPercent signal change (Mean)
Oxytocin0.54
Placebo0.27

[back to top]

Difference in Cry Rating Scores Between AVP and Placebo

"The effect of the drug will be assessed by analyzing the differences between ratings of infant cries under AVP and placebo treatment on a 7-point likert scale. Sixteen adjectives will be used to describe two different cries. Participants will rate each cry from 1-7 where one represents not at all and 7 represents extremely. Difference is defined as AVP minus placebo scores." (NCT02223429)
Timeframe: Baseline, Visit 2 (Up to 10 days)

,
Interventionunits on a scale (Mean)
Cry 1 GratingCry 1 UrgentCry 1 PiercingCry 1 AversiveCry 1 CompellingCry 1 ManipulativeCry 1 SpoiledCry 1 IrritatedCry 1 SympatheticCry 1 AlarmedCry 1 AngryCry 1 UpsetCry 1 CompassionateCry 1 DistressedCry 1 AnnoyedCry 1 TenderCry 2 GratingCry 2 UrgentCry 2 PiercingCry 2 AversiveCry 2 CompellingCry 2 ManipulativeCry 2 SpoiledCry 2 IrritatedCry 2 SypmatheticCry 2 AlarmedCry 2 AngryCry 2 UpsetCry 2 CompassionateCry 2 DistressedCry 2 AnnoyedCry 2 Tender
Placebo4.065.314.193.815.002.691.943.444.384.381.812.634.943.312.254.193.385.253.563.445.002.382.312.634.944.252.002.884.753.061.884.50
Vasopressin (AVP)4.695.444.813.944.563.062.443.445.064.881.943.004.883.312.504.003.255.133.133.444.502.632.192.134.884.312.133.194.883.062.194.44

[back to top]

Mean Percent Signal Change in Right Medial Orbitofrontal Cortex

The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI). Changes will be assessed in the OT group only per protocol. (NCT02223429)
Timeframe: Baseline, Visit 2 (Up to 10 days)

InterventionPercent signal change (Mean)
Oxytocin-0.22
Placebo-0.53

[back to top]

Liver Dysfunction as Characterized by Transaminase Levels

Transaminase levels (alanine and aspartate, measured in IU/L ) will be tracked for all patients and changes will be compared between study groups. (NCT03088345)
Timeframe: 48 hours post-operative

InterventioniU/L (Mean)
Vasopressin, Arginine715
Placebo522

[back to top]

Renal Dysfunction as Characterized by Change in Cystatin Level

Cystatin levels will be measured at baseline (immediately before cardiopulmonary bypass) 24 hours postoperative. The change (postoperative minus baseline) in cystatin level will be compared between groups. (NCT03088345)
Timeframe: from baseline pre-cardiopulmonary bypass to 24 hours post-operative

Interventionmg/L (Mean)
Vasopressin, Arginine0.095
Placebo0.017

[back to top]

Resource Utilization Measured by Length of Stay (LOS)

Length of stay (LOS) measured in postoperative hours compared between groups (NCT03088345)
Timeframe: from time of operation until hospital discharge

Interventionhours (Mean)
Vasopressin, Arginine180
Placebo203

[back to top]

Hemodynamics as Characterized by Mean Arterial Pressure

Organ perfusion pressure measured as Mean Arterial Pressure (MAP). It will be measured hourly for 24 postoperative hours for all subjects and compared between the two study groups over the whole time of observation as the main between-group effect in panel regression. (NCT03088345)
Timeframe: 24 hours post-operative

InterventionmmHg (Mean)
Vasopressin, Arginine67
Placebo66

[back to top]

Hemodynamics as Characterized by Transpulmonary Pressure Gradient

The transpulmonary pressure gradient (TPG), defined as the difference between mean pulmonary arterial pressure (Ppa) and left/common atrial (common atrial) pressure (Pla) will be measured hourly for 24 postoperative hours for all subjects and compared between the two study groups over the whole time of observation as the main between-group effect in panel regression. (NCT03088345)
Timeframe: 24 hours post-operative

InterventionmmHg (Mean)
Vasopressin, Arginine6.4
Placebo8.3

[back to top]

Hemodynamics as Characterized by Vasoactive Inotrope Score (VIS)

The vasoactive inotrope score (VIS) is a linear sum of vasoactive and inotrope durg infusion doses. It is usually reported as dimensionless but is sometimes reported as normalized to dopamine mcg/kg/min equivalents. The score starts at 0 and has no defined upper limit, with a commonly observed range 0-50. It is used as a measure of the intensity of hemodynamic support, with higher scores indicating more vasoactive drug support for patients. The relationship of VIS to other patient outcomes is not consistent. It will be calculated hourly for all subjects and compared between groups over the entire observation timeframe. (NCT03088345)
Timeframe: 48 hours post-operative

Interventionunits (Mean)
Vasopressin, Arginine11
Placebo11.3

[back to top]

Change in BOLD Singal in Supplementary Motor Area Compared to Whole Brain Average During the Painful Stimulation

"Blood oxygenation level dependent (BOLD) responses will allow the identification of relative activation/deactivation in the brain as a result of events (e.g. painful stimulations) that will be given during the experiment.~Changes in the Percentage of BOLD signal are calculated as the BOLD signal in the right supplementary motor area during the 20-second heat pain divided by the whole-brain average BOLD signal during that 20-second heat pain." (NCT03446456)
Timeframe: Day 2, the average of 24 trials of painful stimulations with each stimulation lasting 20 seconds

Interventionpercentage of BOLD signal change (Mean)
Saline0.485
Arginine Vasopressin0.482

[back to top]

Heating Temperature

On Day 1, the heating temperature was calibrated to the individual level. The heating temperature corresponding to 50 out of 100 visual analog scale pain ratings was selected as the testing temperature for day 2 (test). (NCT03446456)
Timeframe: Day 1 (calibration)

Interventioncelsius degree (Mean)
Saline44.16
Arginine Vasopressin44.44

[back to top]

Implicit Association Test (IAT) Response Latency Difference

"The IAT is a behavioral test that examines racial biases via measuring the strength of associations between concepts (e.g., African-American, Asian, White) and evaluations (good, bad). Participants were asked to press a response key when they saw images (people) or words (good/bad) on the screen. Response latencies (RL) were measured in milliseconds using E-prime as the reaction time to press the response key. An RL difference (D) score was calculated as 1) Compute the standard deviation (SD) of RL from overall trials; 2) M1 is the mean of RL in the condition where White and good share the same response key. M2 is the mean of RL in the condition where African-American/Asian people and good share the same response key; 3) D = (M2-M1)/SD.~The D score ranges from -2 to +2. Positive values indicate a racial preference for White people. Negative values indicate a racial preference for African-American/Black or Asian people. A value close to 0 indicates no racial preference." (NCT03446456)
Timeframe: Day 1

Interventiondifference score (Mean)
Saline0.03
Arginine Vasopressin0.07

[back to top]

Pain Ratings

Participants will provide their pain on a Visual Analogue Scale raging from 0=no pain to 100= maximum unbearable pain. Normal value will be absence of pain. (NCT03446456)
Timeframe: Day 2 (test)

Interventionunits on a scale (Mean)
Saline44.84
Arginine Vasopressin47.19

[back to top]

Pain 10 Minutes Post Procedure

Distance (mm) from the left of the 100-mm Visual Analog Scale (VAS) (reflecting magnitude of pain) recorded 10 minutes after the completion of the procedure. Pain will be assessed using a 100 mm visual analogue scale with the anchors 0 = none, 100 mm = worst imaginable. (NCT03636451)
Timeframe: Once 10 minutes after the procedure on the day of recruitment, approximately one minute.

Interventionunits on a scale (Median)
20cc 1% Lidocaine With 2 Units of Vasopressin Paracervical Block26
40cc Buffered 0.5% Lidocaine With 2 Units of Vasopressin Paracervical Block11

[back to top]

Overall Pain

Distance (mm) from the left of the 100-mm Visual Analog Scale (VAS) (reflecting magnitude of pain) recorded after the procedure reflecting the overall pain felt during the procedure. Pain will be assessed using a 100 mm visual analogue scale with the anchors 0 = none, 100 mm = worst imaginable. (NCT03636451)
Timeframe: Once 10 minutes after the procedure on the day of recruitment, approximately one minute.

Interventionunits on a scale (Median)
20cc 1% Lidocaine With 2 Units of Vasopressin Paracervical Block57
40cc Buffered 0.5% Lidocaine With 2 Units of Vasopressin Paracervical Block56

[back to top]

Pain With Cervical Dilation

Distance (mm) from the left of the 100-mm Visual Analog Scale (VAS) (reflecting magnitude of pain) recorded at time of cervical dilation. Pain will be assessed using a 100 mm visual analogue scale with the anchors 0 = none, 100 mm = worst imaginable. (NCT03636451)
Timeframe: Once during the procedure on the day of recruitment, approximately one minute. During procedure at time of cervical dilation.

Interventionunits on a scale (Median)
20cc 1% Lidocaine With 2 Units of Vasopressin Paracervical Block52
40cc Buffered 0.5% Lidocaine With 2 Units of Vasopressin Paracervical Block45

[back to top]

Pain With Uterine Aspiration

Distance (mm) from the left of the 100-mm Visual Analog Scale (VAS) (reflecting magnitude of pain) recorded immediately after uterine aspiration. Pain will be assessed using a 100 mm visual analogue scale with the anchors 0 = none, 100 mm = worst imaginable. (NCT03636451)
Timeframe: Once during the procedure on the day of recruitment, approximately 1 minute. During procedure immediately after uterine aspiration.

Interventionunits on a scale (Median)
20cc 1% Lidocaine With 2 Units of Vasopressin Paracervical Block46
40cc Buffered 0.5% Lidocaine With 2 Units of Vasopressin Paracervical Block58

[back to top]

Number of Participants That Survived 30 Days

(NCT03640949)
Timeframe: At 30 days

InterventionParticipants (Count of Participants)
Vasopressin and Methylprednisolone23
Placebo31

[back to top]

Number of Participants With Return of Spontaneous Circulation

Return of spontaneous circulation is defined as spontaneous circulation with no further need for chest compressions sustained for at least 20 minutes (NCT03640949)
Timeframe: During the cardiac arrest, an average of 20 minutes

Interventionparticipants (Number)
Vasopressin and Methylprednisolone100
Placebo86

[back to top]

Number of Participants With a Favorable Neurological Outcome at 30 Days

A favorable neurological outcome will be defined as a cerebral performance category score of 1 or 2. The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes. (NCT03640949)
Timeframe: At 30 days

InterventionParticipants (Count of Participants)
Vasopressin and Methylprednisolone18
Placebo20

[back to top]

Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio)

In patients with pulmonary hypertension (PH) one anticipates a greater increase in pulmonary vascular resistance as opposed to systemic vascular resistance when vasopressors are administered. (NCT05439460)
Timeframe: Day 1 (at baseline and up to 5 minutes following study drug administration) (Q: 2 minutes - 2 to 5 minutes?)

,,
InterventionRp:Rs ratio (Mean)
BaselineApprox. 2 minutes following drug administration
Arginine Vasopressin0.750.49
Epinephrine0.610.6
Phenylephrine0.80.73

[back to top]